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Level of
evidence:
Selection of the literature was performed
following the pyramid of evidence, with
aggregated evidence in the top of the pyramid
(systematic reviews, meta-analysis), then
randomized controlled trials, then observational
studies. Single case reports, animal studies, and in
vitro studies in the bottom of the pyramid were
excluded, leaving expert opinions at the bottomof
the pyramid. The level of evidence per section in
the guideline is dependent on the level of
evidence available on the speciﬁc subject.
Sample size: If there were large studies available, with a
minimum of 15 subjects per research group, only
these were included. If not available, smaller
studies were also included.INTRODUCTION
Members of this Guideline Writing Committee (GWC) were
selected by the European Society for Vascular Surgery
(ESVS) to represent physicians involved in management of
patients with chronic venous disease (CVD). The members
of the GWC have provided disclosure statements of all
relationships that might be perceived as real or potential
sources of conﬂicts of interest. These disclosure forms are
kept on ﬁle at the headquarters of the ESVS. The GWC
report received neither ﬁnancial support nor support from
the ESVS or any pharmaceutical, device, or surgical
industry.
The ESVS guideline committee was responsible for the
endorsement process of this guideline. All experts
involved in the GWC have approved the ﬁnal document.
The guideline document was reviewed and approved
by the EJVES editorial board and ESVS guideline
committee.
THE PURPOSE OF THESE GUIDELINES
The ESVS has developed clinical practice guidelines for the
care of patients with CVD in the lower extremities.
The aim of this document is to assist physicians
in selecting the best management strategy for patients
with CVD. This guideline, established by members of the
GWC, who are members of the ESVS or non-
members with speciﬁc expertise in the ﬁeld, is based
on scientiﬁc evidence completed with expert opinion on
the matter. By summarizing and evaluating all available
evidence in the ﬁeld, recommendations for the evaluation
and treatment of patients with CVD have been
formulated.
Guidelines have the purpose of promoting a standard of
care according to specialists in the ﬁeld, in this case repre-
sented by members of the ESVS. However, under no
circumstance should this guideline be seen as the legal
standard of care in all patients. As the word guideline states
in itself, the document is a guiding principle, but the care
given to a single patient is always dependent on the indi-
vidual patient (symptom variability, comorbidities, age, level
of activity, etc.), treatment setting (techniques available),
and other factors.
The recommendations are valid only at the time of
publication, as technology and disease knowledge in this
ﬁeld changes rapidly and expanding recommendations can
become outdated. It is an aim of the ESVS to revise the
guidelines when important new insights in the evaluation
and management of CVD become available.METHODOLOGY
Strategy
The GWC was convened in 2011 at the annual ESVS meeting
in Athens. At that meeting the tasks in creating the guide-
line were evaluated and distributed among the committee
members. The ﬁnal version of the guideline was submitted
on December 22, 2014.
Literature search and selection
A clinical librarian performed the literature search for this
guideline systematically in PubMed, Embase, Cinahl, and
the Cochrane Library up to January 1, 2013. Reference
checking and handsearch by the guideline committee
members added other relevant literature.
The members of the GWC performed the literature se-
lection based on information provided in the title and ab-
stract of the retrieved studies.
Criteria for search and selection were:Several relevant articles published after the search
date or in another foreign language were included, but only
if they were of paramount importance to this guideline.Weighing the evidence
To deﬁne the current guidelines, members of the
GWC reviewed and summarized the selected literature.
Conclusions were drawn based on the scientiﬁc
evidence.
The guidelines in this document are based on the Euro-
pean Society of Cardiology grading system. For each
recommendation, the letter A, B, or C marks the level of
Table 1. Levels of evidence.
Table 2. Classes of recommendations.
682 C. Wittens et al.current evidence (Table 1). Weighing the level of evidence
and expert opinion, every recommendation is subsequently
marked as either class I, IIa, IIb, or III (Table 2). The lower
the class number, the more proven is the efﬁcacy and safety
of a certain procedure.
CHAPTER 1: GENERAL CONSIDERATIONS
The term CVD has been used to describe both visual and
functional manifestations of abnormalities in the peripheral
venous system. It can be deﬁned as “(any) morphological
and functional abnormalities of the venous system of long
duration manifest either by symptoms and/or signs indi-
cating the need for investigation and/or care.”1
The prevalence of CVD in the adult population has been
reported to be as high as 60%, particularly affecting pop-
ulations in the developed world.2,3 It has become clear that
CVD is an important cause of patient distress and signiﬁ-
cantly impacts on healthcare resources.4,5
Although a complete understandingof thepathophysiology
of CVD remains elusive, chronic venous hypertension iswidely
accepted as the predominant cause of advanced venous skin
changes and ulceration. A sound understanding of the disease
process and its clinical presentations is paramount in assess-
ment and management of the patient with CVD.1.1. History
1.1.1. Pathophysiology
In ancient times, venous problems were described occasion-
ally. Hippocrates (460e377 before Christ) stated that an up-
right position was inappropriate for a leg with ulceration,
assumingly not knowing the real background at that time. In
1544, a Spanish anatomist, Vassaseus, gave a description of
venous valves and their function.6 At the beginning of the
seventeenth century, Harvey published his contribution to the
understandingof thephysiologyof the venous circulation, and
Malpighi demonstrated the existence of capillaries and
thereby clariﬁed the ﬁnal connection in the circulatory sys-
tem.7 At the same time, Brodie described symptoms and signs
of chronic venous insufﬁciency (CVI).8 In 1670, Lower
described venous return as a result of the arterial propagating
pulsation (“vis a tergo”), and also described the muscle
pump.7 The pressure changes caused by thoracoabdominal
respiration, enhancing the venous returne “vis a fronte”e to
the heart, were described in 1710 by Valsalva.7
In 1891, the classical test was invented to differentiate be-
tween superﬁcial and deep reﬂux/retrograde ﬂow by Tren-
delenburg, and5 years later a test to verify patencyof the deep
veins was proposed by Perthes, both tests using compression
of the limb.7 Homans pointed out that ulcerationwas different
in behaviour dependent on whether it was a result of super-
ﬁcial or deep disease.9 Linton introduced the concept of
ambulatory venous hypertension as the fundamental patho-
physiologic theory for terminal and distinct CVD.10
1.1.2. Treatment
Hippocrates recommended puncture of varicose veins fol-
lowed by compression.8 Four-hundred years later, Celsus
performed an avulsion technique with hooks of varicose
veins.The French surgeon Pravaz has been given credit for the
design of the syringe and needle technique for vascular in-
jection in 1831, and later Pétrequin introduced the method of
sclerotherapy for varicose veins. After unsatisfactory results
by Smith in 1939, the technique was discredited for many
years.11 In 1944, Orbach introduced the so called “air-block”
technique to avoid dilution of the injected sclerosant and, at
the same time, create close contact with the endothelium,
which indeedwas a step forward and also a precursor towards
foam sclerotherapy.12 Trendelenburg proposed great saphe-
nous vein (GSV) ligature atmid-thigh in 1891 as being a step to
control distal varicosities.13 The most used methods have
been the external stripping byMayo and the Babcock method
with the intraluminal technique, both at the beginning of the
twentieth century, and later pin-stripping by Oesch in 1963.14
Muller revisited the accompanying hook phlebectomy in 1956
through minimal incisions.15
Elastic stockings were invented in 1930 as a result of the
personal experience of Jobst, an engineer, who himself
suffered from a venous ulceration. While bathing in his
pool, he noticed that his symptoms were less pronounced,
coming to the conclusion that the increasing depth of the
water was the secret of the “healing” component. Thus,
graduated compression stockings were invented.16
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Bypass procedures were popularized as the May-Husni
operation at the femoral level,17 and the Palma operation
for iliac occlusion.18 Gloviczki presented experimental work
on abdominal bypass surgery with prosthetic grafts and
arteriovenous ﬁstulae some years later.19 Eklöf suggested the
beneﬁt of using an arteriovenous ﬁstula after iliac throm-
bectomy.20 At the same time, the pioneers Kistner and Raju
performed valve reconstructions and valve transfer.21,22
Hauer introduced subfascial endoscopic perforator surgery
(SEPS) in 1985.23 Balloon dilatation and implantation of stents
in the venous system was published for the ﬁrst time in 1991
by Okrent using ballooning and in 1994 by Semba, who used
the more durable stenting technique. Both procedures were
used as additional treatments to catheter directed throm-
bolysis at the ilio-femoral level.24,25 Stenting of iliac obstruc-
tion in patients with CVI was popularized by Néglen in 2000 in
a large scale study.26
The endovenous procedures for varicose veins were
developed in the 1990s as thermal, chemical, and mecha-
nochemical vein ablation for truncal varicose disease but
were based on the initial work of electro puncture and
cauterizations of varicose veins dating back to the 1960s.
1.2. Epidemiology
Clinical reporting, usually indicated as the C of the CEAP
classiﬁcation (from C0 to C6, see further 2.2.1) makes it
possible to report prevalence numbers for each clinical class as
well as progression rates through the clinical classes over time
and relationship to gender, age, obesity, and other risk factors.
The prevalences of CVD differ according to these risk factors.
The newest and most comprehensive epidemiologic studies
from this century will be presented here. Telangiectasiae (also
known as spider veins) (C1) have been reported to affect up to
80% of the population.2 Varicose veins (C2) are also extremely
common,with a variable reported incidence ranging from 20%
to 64%.2,27e29 The more advanced stages of venous disease,
CVI (C3eC6), appear to affect about 5% of the population,
with the prevalence of the end stages of CVI (active and healed
venous ulcers, C5þC6) estimated at 1e2%.30
1.2.1. Risk factors
1.2.1.1. Age. Several studies have revealed older age as the
most important risk factor for varicose veins and CVI. In the
San Diego study, older age showed a signiﬁcant odds ratio
(OR) up to 2.42 for varicose veins and up to 4.85 for CVI.31
In the Bonn Vein study, the most important risk factor for
varicose veins and CVI was older age (OR in the age 70e79
years were 15.9 for varicose veins and 23.3 for CVI).32
1.2.1.2. Gender. C2 disease is more common in female
adults than male adults: 13.9e46.3% females and 11.4e
29.3% males based on 50,974 persons with most between
16 and 90 years in the ﬁve classical studies from Europe and
the USA.31e35 In the same studies, C3 varied from 4.5% to
13.6% and the prevalence of C4eC6 varied from 3.6% to
12%.31e33,35 A similar prevalence of C2 was found in women
who had never been pregnant, and in men.36 In the same
studies, the inﬂuence of gender on C0eC1 is inconclusive.However, it has to be mentioned that in the Edinburgh Vein
study, varicose veins (C2) were more common among male
subjects in the general population.29
The incidence of varicose veins per year is 2.6% in women
and 1.9% in men.37 The gender inﬂuence diminishes with
age.38 No obvious gender difference is shown concerning
CVI.32,34,35
Oral hormone replacement and contraceptives do not in-
crease the risk of varicose veins.32,39 The number of preg-
nancies increased the OR from 1.3 to 2.2 for development of
varicose veins.32 Another recent large scale study could not
demonstrate change in GSV reﬂux following pregnancies.40
Half of the general population in the Bonn Vein study
reported venous symptoms, 49.1% of the males and 62.1%
of the females, and the prevalence increased with age.41
Symptoms were more frequently reported in limbs with
deep venous involvement compared with superﬁcial, and
were also more frequent in women.31
In a recent global collection of prospective epidemiologic
data on chronic venous disorder in 91,545 subjects including
areas outside Europe and the USA, almost the same obser-
vations weremade, but on a larger scale. Symptomatic C0was
more frequent in men and C2eC3 more frequent in women,
but C4eC6 did not differ between men and women.27
1.2.1.3. Obesity. A body mass index (BMI) greater than 30
increases the risk for CVI signiﬁcantly, with ORs for men and
women of 6.5 and 3.1, respectively.41 Another study found
a positive correlation between a BMI of more than 30 and
varicose veins (OR 5.8) in postmenopausal women.42 Other
authors found an association between severe obesity (BMI
40 or more) and increasing limb symptoms without
anatomic evidence of venous disease, suggesting that the
obesity itself contributed to the venous insufﬁciency.43
Similar ﬁndings were published in a larger scale investiga-
tion with a threshold of BMI of 25.44
1.2.1.4. Family history. Many studies have shown a corre-
lation between a positive family history for varicose veins or
venous disease and the risk of varicose veins.32 A cohort
study revealed that a family history of hospital treatment for
varicose veins was associatedwith an increased risk of similar
treatment among relatives.45 Responsible genetic distur-
bances have not been found to explain the obvious heredity.
Genome-wide association studies should be considered to
further unravel the genetic basis of venous disease.46
1.2.1.5. Ethnicity. For many years, prevalence studies have
been based on ﬁgures and numbers from the western world.
Data from Europe, Latin America, theMiddle East, and the Far
East are now available in the large scale Vein Consult Program
with 91,545 subjects over 18 years of age. C1eC6 involved
63.9% of the subjects. The incidence of C2 was signiﬁcantly
lower in theMiddle East, whereas C1 was signiﬁcantly higher.
C5 and C6 were unequally distributed in the regions.27
1.2.2. Prevalence of reﬂux
In the Edinburgh Vein study with 1,566 subjects, the aim
was to correlate venous reﬂux with clinical features. Reﬂux
was deﬁned as reversed ﬂow longer than 0.5 seconds. No
reﬂux was found in 36.5% of the patients. One third of the
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tem. The frequency of reﬂux in both superﬁcial and deep
segments increased with the clinical severity of disease. CVI
increased with age. Symptoms were strongly related to the
severity of CVI.47 Pattern of reﬂux has also been examined
in the Bonn Vein study with 3,072 subjects.48 Pathological
reﬂux was deﬁned as longer than 0.5 seconds. The preva-
lence of superﬁcial reﬂux was signiﬁcantly higher in women,
whereas deep venous reﬂux was signiﬁcantly higher in men.
Both types correlated with progression in C stages, but only
superﬁcial reﬂux showed a marked increase with age.48
1.2.3. Progression of varicose veins
The prevalence of C6 disease varies from 0.1 to 0.5%.32,33
However, this does not reveal the rate of progression from
lower to higher C classes. A study including 116 limbs with
varicose veins used a second duplex scan a median 19months
after the initial examination in the period waiting for surgery.
Approximately one-third of the patients had progression, and
in 95% of the patients the changes were noted after 6 months
or more.49 In the large scale Bonn Vein study, the progression
rate from varicose veins to CVI was 4% per year.501.3. Anatomy
1.3.1. The superﬁcial veins of the lower extremity
The full length of the GSV is covered by a connective tissue
lamina called the “saphenous fascia,” and typically lies in
the saphenous compartment.51 On B-mode ultrasound it
resembles an “Egyptian eye” in transverse scan with the
saphenous fascia easily being identiﬁed.52 In the GSV
compartment there is usually only one truncal vein. Very
rarely (in 1% of patients) the GSV is duplicated, which
means two veins are situated in the same saphenous
compartment.53
A few millimetres distal to the saphenofemoral junction
(SFJ), the GSV has a terminal valve, and a few centimetres
distal to that valve there is often another valve, called the
pre-terminal valve.54,55 Important tributaries (i.e. superﬁcial
circumﬂex iliac, superﬁcial epigastric, and superﬁcial
external pudendal veins) join the GSV between these
valves. The anterior accessory saphenous vein (AASV) and
the posterior accessory saphenous vein (PASV) are
frequently present and run parallel to the GSV in the thigh
in their own saphenous compartment.
The SSV ascends upwards on the posterior aspect of the
calf between the two heads of the gastrocnemius muscle. In
the popliteal fossa, the main trunk of the SSV frequently
drains into the popliteal vein. Often, a cranial extension of
the SSV, called the “thigh extension,” continues upwards
and uncommonly the SSV does not drain into the popliteal
fossa but instead continues cranially and eventually empties
into the femoral vein or the GSV. Veins connecting the GSV
and SSV are called “intersaphenous veins.” A particular
intersaphenous vein is the Giacomini vein running from the
SSV in the popliteal fossa to the GSV.55 The SSV lies in its
own saphenous compartment, delineated by the superﬁcial
fascia and the muscular fascia.56,57Perforating veins are variable in arrangement and distri-
bution, and are numerous (more than 100 in each limb). The
medial perforating veins are most signiﬁcant but their role
in CVI and venous ulcers is not well deﬁned.58e61
1.3.2. The deep veins of the lower extremity
Venous blood from the foot drains through the deep plantar
venous arch, which at the medial malleolus becomes the
posterior tibial veins.62 On the dorsum of the foot the deep
dorsal digital veins drain into the dorsal metatarsal veins. The
dorsalis pedis vein located on the dorsumof the foot becomes
the anterior tibial veins at the ankle. The tibioperoneal trunk
and the anterior tibial veins join and form the popliteal vein in
the popliteal fossa.
The main tributaries of the popliteal vein are the gastroc-
nemius veins, the tibial veins, and the SSV, although the
gastrocnemius veins may join the SSV before joining the
popliteal vein. The saphenopopliteal junction (SPJ) is often
located within 5 cm of the popliteal skin crease, but this level
varies.
The popliteal vein continues in a cephalad direction, and
ascends in the adductor canal becoming the femoral vein
(the previously used term “superﬁcial femoral vein” has
been abandoned).63 Approximately 10 cm below the
inguinal ligament, the femoral vein joins with the deep
femoral vein to form the common femoral vein. The com-
mon femoral vein is situated medially to the corresponding
artery and it ends at the inguinal ligament. The vein receives
the GSV at the SFJ. Both the popliteal and the femoral vein
may be duplicated in segments of various lengths.64,65
Above the inguinal ligament the common femoral vein
continues as the external iliac vein, and at the junction of
the internal and external iliac veins anterior to the sacroiliac
joint they form the common iliac vein.
As well as the superﬁcial veins, the deep veins contain
valves. The frequency of valves increases from the more
proximal veins to the more distal. The calf veins contain
numerous valves, whereas the femoral and popliteal veins
have only one or two valves.66,67 Additional valves are seen,
however, in the femoral vein near the junction with the deep
femoral vein. The common femoral vein usually contains only
one valve. Cranial to the SFJ, there is only one or no valve. In
the common iliac vein, valves are practically absent or rudi-
mentary, andvalves are absent in the inferior venacava (IVC).66
1.4. Physiology
The venous circulation is a low pressure, low velocity, large
volume, low resistance vascular system. The primary func-
tion of the venous system is to return blood to the heart.
Venous return is inﬂuenced by the interaction between a
central pump (the heart), pressure gradients, the peripheral
venous pump, and competent valves in patent veins. In an
upright position these factors work together to overcome
the hydrostatic pressure induced by gravity, which is quite
different in the supine position. Furthermore, the system is
characterized by its capacitance, which allows pronounced
ﬂuid variations. Finally, the system has an impact on the
regulation of body temperature.
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output. The venous system contains at least 60% of total
resting blood volume, with half of this being in the post-
capillary venules in the lower extremity. About 25% re-
sides in the splanchnic circulation.68,69
1.4.1. The relationship of capacitance/volume to pressure
Variations in venous blood volume of up to 10e20% are
tolerated.68,70 A simple shift from a supine to an upright
position can be responsible for a 10% volume change in the
lower extremity.69 An increase in capacitance is normal late in
the day after standing or sitting, and almost 20% of normal
volunteers will demonstrate valvular dysfunction.71
The system has a unique function based on the vein
compliance.Tomaintain anacceptable lowpositivepressure of
5 mmHg, the veins become ﬂaccid, and the pressure can even
be negative with minimal volume. In contrast, a considerable
increase in volume will result in only a relatively modest
change in pressure. A change in vein shape from elliptic to
circular indicates high volume and high pressure. In other
words: over a normal pressure range of 5e25 mmHg, volume
can change remarkably without affecting either ﬂow or
pressure.70
1.4.2. The hydrostatic and dynamic pressure
In the non-supine situation, gravity exercises a hydrostatic
inﬂuence on the venous system.The hydrostatic pressure at a
given anatomical point is determined by measuring the ver-
tical distance between the heart and the point of interest.72 In
the upright position, the hydrostatic pressure, measured in a
dorsal foot vein, is determined by the blood column between
the right atrium and the foot. For example in a person 175 cm
tall, the venous pressure at the foot may reach approximately
95mmHg, with the pressure at the groin being 30e35mmHg,
dependent on the anthropometric shape of the body.
The dynamic pressure is basically caused by propagation of
arterial pulsation from the pumping heart. Through pre-
capillary arterial vasoconstriction - among other factors -
most of the dynamic pressure is decreased, resulting in a
pressure of 12e18 mmHg in the venous side of the capillary.
The atrial pressure of 4e7mmHg causes the resulting dynamic
pressure gradient to facilitate return of blood to the heart in
the supine position. The respiratory inﬂuence is positive for
venous return. Inspiration creates a negative pressure in the
thoracic cavity, creating a kind of “suction” of blood, while
increased abdominal pressure during inspiration reduces ﬂow
in the abdomen. During expiration the opposite ﬂowpattern is
seen. This mechanism is mostly seen in the supine position.73
1.4.3. The vein valves
The valves divide the column of blood into segments and
prevent retrograde ﬂow.74 The greater number of valves in the
infrapopliteal segment suggests their greater functional
importance at this level.75 A normal valve can resist a pressure
above 300 mmHg, but reﬂux will occur at a higher pressure. In
patients with superﬁcial or deep vein valvular imcompetence
reﬂux develops at a much lower pressure because of valve
disease and/or vein dilatation.73 In the presence of normal
valve function the blood is conducted from the superﬁcialveins to the deep veins through the perforating system. An
exception is the perforating veins in the foot, where bidirec-
tional ﬂow is normal.75 One study has described the valves
creating jet streams in the venous system.76 Thisﬂowpattern is
later described as helical, especially at venous junctions.77
1.4.4. The calf muscle and the foot pump
These pumps act together during walking. Intramuscular
pressure can increase up to 200e300 mmHg, creating a
pressure three times higher in the muscle veins than in the
superﬁcial veins, thus creating a pressure gradient cranially
and from the calf.78 During relaxation the blood is directed
from the superﬁcial veins to the deep veins, with the lowest
pressure at this stage. The foot pump is quite different in
function with elongation of the plantar veins during walking,
thus squeezing the blood antegradely.79 The compression of
the plantar venous plexus during walking is a primer of the calf
pump.62Half of the blood can be ejected upwards in one single
contraction.80,81 The contribution of thigh muscle contraction
is minimal compared with the above mentioned pumps.81
1.4.5. Venous tone
Venous tone is managed by the muscle layer in the vein
wall. Several mechanisms, such as sympathetic-adrenergic
nerve activity, circulating vasoactive substances, and local
metabolites will stimulate it.73
1.4.6. The venous pump: main transport system in the
non-supine position
In an upright position venous return is still inﬂuenced by the
dynamic effect from the heart. The increase in hydrostatic
pressure is the same in both the arteries and veins. Fortu-
nately the potent veno-arterial reﬂex, activated by the venous
dilatation, involves an arteriolar constriction restricting the
arterial blood ﬂow by 50%.73,82 Even in a so called relaxed
standing position therewill bemuscle contractions, whichwill
diminish the capillary pressure distally in the extremity. With
use of the muscle pumps and the valves, together called the
venous pump, the pressure distally will be decreased to
approximately 30mmHg during walking or tiptoe/heel raising
manoeuvres. This pressure is called the ambulatory venous
pressure (AVP), which can bemonitored through a needle in a
foot vein. Measuring AVP is potentially meaningful. It has
been shown that no ulceration was observed in limbs with
AVP less than 30 mmHg, but there was 100% incidence with
AVP above 90 mmHg.831.5. Pathophysiology
The pathophysiology of CVD is characterized by reﬂux,
obstruction, or a combination of both. This results in reduced
ability to empty the leg veins efﬁciently during exercise, which
means theAVP remains high and this eventually leads to all the
clinical features of venous hypertension. Apart from reﬂux and
obstruction, other underlying factors may compromise
adequate venous emptying, such as failure of the calf and foot
muscle pump (decreased mobility of the ankle joint and other
neuromuscular problems).80,83,84 Whereas most patients with
uncomplicated varicose veins (C2) still have normal venous
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stages of CVD progressively develop venous hypertension,
characterized by symptoms and signs of CVI (C3eC6). The
clinical manifestations of CVI are oedema and skin changes,
from hyperpigmentation, eczema, atrophie blanche and lip-
odermatosclerosis to venous ulcers.
Deep vein valve incompetence will result in minor or no
reduction in AVP, and venous obstruction will even elevate
the pressure during calf contractions, both representing
ambulatory venous hypertension.85,86 Outﬂow obstruction
at ilio-femoral level with or without valvular incompetence
in the femoral and/or popliteal vein can lead to venous
claudication described as a “bursting” pain while walking,
only relieved by rest or even better by elevation. In multi-
level post-thrombotic obstruction, the iliac vein lesions are
the key pathology as infrainguinal obstructions are better
tolerated because of adequate collateralization.87 The
pathophysiological combination of reﬂux and obstruction is
signiﬁcantly more common in patients with venous ulcera-
tion than in those with less advanced stages of CVD.88
1.5.1. Venous reﬂux and obstruction
In incompetent superﬁcial veins, reﬂux is primarily caused by
vein wall abnormalities.89,90 Varicose veins contain an
increased amount of collagen and decreased number of
smooth muscle cells and elastin leading to disorganization of
muscle components, disruption of elastic ﬁbres, and
ﬁbrosis.91e93 The weakness of the vein wall results in dilata-
tion and enlargement of the valve ring, making the valve
unable to work sufﬁciently, with reﬂux as the consequence.94
The reﬂux can be axial or segmental. For many years, it has
been accepted that this process starts cranially, mainly at the
level of the SFJ or SPJ, and from there extends to the main
trunks and further to the superﬁcial tributaries. This is the so
called “descending” pathophysiological theory. More recent
research has proposed a rather multifocal origin of varicose
veins, which states that, ﬁrst, tributaries become dilated and
incompetent, and only thereafter the main trunks, and
eventually the junctions. This corresponds with the
“ascending” theory of varicose vein development.95
The pathology in the deep veins is more complex. Acute
obstruction occurs in the case of deep vein thrombosis.This is
not discussed further in the present guideline. Chronic
obstruction, resulting in increase of resistance to blood ﬂow, is
mainly caused by post-thrombotic changes consisting of ste-
nosis, occlusion, intraluminal synechia, and increased rigidity
of the vein wall, or any combination of these abnormalities.96
Valves may be damaged and collaterals will develop at any
place parallel to a deep obstruction, and even these can be
incompetent. Chronic deep venous incompetence occurs in
80% of cases because of post-thrombotic valvular changes,
and in 20% because of primary valvular incompetence.75
Ilio-femoral venous occlusion is less likely to recanalize
comparedwith other venous segments. Almost two thirds will
remain more or less obstructed with variable collateraliza-
tion.97 Obstruction in combinationwith reﬂuxoccurs in 55% of
symptomatic patients.97,98 In patients with ulceration, the
cause is distributed almost equally between superﬁcial anddeep venous incompetence.99 Perforator incompetence has
proven to be a signiﬁcant factor in the determination of CVD
severity.100
CHAPTER 2: CLINICAL PRESENTATION OF CVD
2.1. Clinical presentation
The symptoms of CVD are extremely variable and cause
signiﬁcant morbidity to patients, negatively impacting on
quality of life (QoL).101,102 Self reported symptoms are
worse in women.5,35 Patients present with heaviness,
tiredness, itching of the skin, nocturnal cramps, and
throbbing and aching of the legs, which is exacerbated by
prolonged standing.16 These symptoms can interfere with
day to day activities and work, particularly in patients who
need to stand for prolonged periods of time. Symptoms are
worse at the end of the day, and symptomatic relief may be
achieved by leg elevation, mobilization, and exercise.
In patients with chronic outﬂow obstruction, venous clau-
dication may typically occur during walking or climbing stairs.
Superﬁcial veins can thrombose, resulting in painful
thrombophlebitis and localized cellulitis. Deep venous
thrombosis, particularly if found in the ilio-femoral segment,
may lead to the development of venous claudication, a
bursting pain affecting the buttocks, thighs, or legs when
walking, requiring rest and leg elevation to achieve symp-
tomatic relief.
Uncommonly, bleeding can be a presentation of CVD. This
is commonly associated with a traumatized superﬁcial var-
icosity, but signiﬁcant bleeding can also arise from an area
of ulceration. The resulting blood loss may be profound and
even life threatening.103
Studies have demonstrated that clinical signs correlate
with patterns of venous reﬂux as identiﬁed by duplex ul-
trasound (DUS) examination. This is true for the superﬁcial
venous system (including both great and small saphe-
nous)104 and the deep venous system.47 There is evidence
suggesting that clinical signs of disease also correlate with
GSV vein diameter, with increasing diameter being associ-
ated with greater disease severity.105
QoL scores also correlatewith disease severity. Patientswith
more severe signs and symptoms report worse QoL scores.106
Clinical recurrence of varicose veinsmay present in a similar
fashion to primary superﬁcial venous disease. A multicentre
study was performed to assess the presence of recurrence in
patients who had undergone previous varicose vein sur-
gery.107 Following the CEAP classiﬁcation,123 the vast majority
had recurrence associated with oedema (C3) (70.9%), while
29.1% had skin changes (C4). Varicose veins were present in
24.6% (C2), in 43% two clinical classes were present, and in
24% four classes were present. There was a mixture of C0eC6
classes, from reticular veins and telangiectasiae, to varicose
veins, oedema, hyperpigmentation, and ulceration.
2.2. Classiﬁcation of chronic venous disease
The diverse nature of presenting signs and symptoms of
patients with CVD means that objective classiﬁcation of
disease severity presents a signiﬁcant challenge.
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anatomical, haemodynamic, or patient reported criteria. A
comprehensive classiﬁcation system would ideally take into
consideration all of these factors.
Dramatic variations and inconsistencies in the assess-
ment of disease severity have made it difﬁcult to interpret
and compare published reports in the literature. The chal-
lenge of inconsistent reporting and the recognition that
there was a need for a uniform, applicable and standardized
classiﬁcation system for venous disease, was the main
motivation for the development of classiﬁcations, particu-
larly the CEAP classiﬁcation.
2.2.1. Clinical Etiological Anatomical Pathophysiological
(CEAP) classiﬁcation
The CEAP classiﬁcation was published in 1994 by an inter-
national ad hoc committee of the American Venous Forum
and endorsed by the Society for Vascular Surgery.108
Following the meeting, it was published in 26 journals
and books and in nine languages, making it a truly universal
document in the ﬁeld of CVD. It was revised in 2004 and is a
widely endorsed classiﬁcation system for clinical papers
reporting on CVD (Table 3).109
The CEAP classiﬁcation system was developed to take
into account not only clinical (C) aspects of venous disease,
but also etiological (E), anatomical (A), and pathophysio-
logical (P) components, enabling a more comprehensive
assessment of the severity of venous disease. The CEAP
classiﬁcation system has largely replaced the previous
severity tools, allowing a standardized approach to the signs
and symptoms of CVD and enabling correlation between
different studies and reports. Nonetheless, CEAP has beenTable 3. CEAP Classiﬁcation.
C: Clinical Classiﬁcation
C0: no visible or palpable signs of venous disease
C1: telangectasia or reticular veins
C2: varicose veins
C3: oedema
C4a: hyperpigmentation or eczema
C4b: lipodermatosclerosis or atrophie blanche
C5: healed venous ulcer
C6: active venous ulcer





Ep: primary (undeterminate cause)
Es: secondary (e.g. post thrombotic)









Pr,o: reﬂux and obstruction
Pn: no venous pathophysiology identiﬁablereported as having moderate inter-observer reproducibility
when deciding medical indication for treatment.110
2.2.1.1. Clinical classiﬁcation: C0eC6. Clinical signs form
the basis of the clinical component of CEAP, which is scored
from 0 (no evidence of venous disease) to 6 (active ulcer-
ation). Although increasing C classiﬁcation is generally
considered to represent increasing disease severity, this
should not be considered a linear progression or severity
score. Unlike the Widmer and Porter classiﬁcations, the
CEAP classiﬁcation allows more detail to be recorded.
Symptoms of CVD, including aching, pain, tightness, skin
irritation, heaviness, and muscle cramps are denoted by the
letter S in subscript, for example C2S (symptomatic) or C2A
(asymptomatic). Even if skin changes have occurred, a pa-
tient may be asymptomatic, for example C5A.
2.2.1.2. Etiological classiﬁcation: Ec, Ep, Es, En. Assessment
and management of CVD varies depending on the under-
lying etiological process. The CEAP classiﬁcation recognizes
and records three different causative factors: congenital
(Ec), primary (Ep), and secondary or post-thrombotic (Es). In
cases where no etiology is found, (En) is used.
Congenital factors are present from birth, and are related
to disorders in the development of the venous system.
Klippel-Trenaunay syndrome (KTS), Parkes-Weber syndrome
(PWS), and vascular malformations are examples of
congenital anomalies.
Primary venous disease commonly results in superﬁcial
venous incompetence, particularly located at the connect-
ing points between deep and superﬁcial veins, SFJ, SPJ, or
perforating veins. Incompetence (or reﬂux) of the superﬁ-
cial venous system may result in venous hypertension and
the development of signs and symptoms of CVD.
Secondary venous disease usually occurs as a result of
previous deep venous thrombosis, although trauma and
intra-abdominal masses may also result in impaired venous
drainage and the development of CVD.
2.2.1.3. Anatomical classiﬁcation: As, Ap, Ad, An. The
anatomical classiﬁcation allows accurate description of the
location of venous disease. The classiﬁcation recognizes
superﬁcial (As), perforating (Ap), and deep (Ad) venous
systems as the site of venous incompetence.
This can be inferred with the aid of clinical tests and the
handheld Doppler probe, but determined much more reli-
ably with DUS examination. Where examination cannot
identify the location of venous incompetence, the patient is
classiﬁed as (An). Superﬁcial disease may affect either the
great or small saphenous systems. Clinical examination and
DUS imaging can provide detailed information to enable
targeted assessment and management planning.
2.2.1.4. Pathophysiological classiﬁcation: Pr, Po, Pr/o, Pn.
The pathophysiological mechanism for CVD has been deﬁned
as reﬂux (Pr), obstruction (Po), both (Pr/o), or not identiﬁed
(Pn). In the advanced CEAP classiﬁcation, the venous system
has been described as 18 named (and numbered) venous
segments, which could be included in the classiﬁcation to
provide a detailed description of CVD in each leg, in an indi-
vidual patient. Although the detailed elaboration in the
advanced CEAP may seem unnecessarily complex or
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accepted and understandable description of all aspects of
CVD.
2.2.1.5. Level of investigation. The diagnostic evaluation of
venous disease can be classiﬁed as111:
 Level 1: history and examination, with or without
handheld Doppler assessment
 Level 2: non-invasive imaging with colour venous duplex
and plethysmography, if available
 Level 3: invasive or complex imaging, including veno-
graphy, computerized tomography, or MR imaging.
2.2.1.6. Applying the CEAP. The CEAP classiﬁcation is widely
accepted as the best available (and most widely used)
classiﬁcation system, and should be used by investigators
reporting on CVD.112 It is important to realize that this is a
measure that can be repeated to classify changes in pa-
tient’s clinical presentation. It should be initialized at the
ﬁrst patient encounter and revised on follow up. Many of
the limitations of CEAP have been addressed during re-
visions, resulting in updated terminology and amended
deﬁnitions.109 However, there are aspects that are not taken
into account by this classiﬁcation system, including mixed
arterial/venous disease, venous neuropathy, venous clau-
dication, corona phlebectatica, and obesity.16 Furthermore,
it has been acknowledged that CEAP cannot be used as a
reliable technique to rationalize patient treatment.113,114
Nevertheless, the CEAP classiﬁcation is currently the most
commonly used assessment tool for venous disease.105,106
2.2.2. Venous Clinical Severity Score, Venous Segmental
Disease Score, and Venous Disability Score
Although the CEAP classiﬁcation provides a descriptive
classiﬁcation tool for patients with CVD, there have been
criticisms that it lacks responsiveness in the long term and
with repeated evaluation of patients. Three other clinicalTable 4. Venous Clinical Severity Score (VCSS).
Attribute Absent (0) Mild (1)
Pain or other discomfort









None Limited to foot or ankle
Skin Pigmentation None or
focal
Limited to perimalleolar ar
Inﬂammation None Limited to perimalleolar ar
Induration None Limited to perimalleolar ar
Number of active ulcers None 1
Active ulcer duration None <3 months
Active ulcer size None Diameter <2 cm
Compression Therapy Not used Intermittent use of stockintools have been described to address some of these
criticisms.
2.2.2.1. Venous Clinical Severity Score: measure of severity.
The Venous Clinical Severity Score (VCSS) was developed to
supplement (rather than replace) the CEAP classiﬁcation.VCSS
offers a broad quantiﬁcation of the severity of venous disease
and is not a detailed descriptive tool for CVD in an individual
patient. It takes into account the disease severity, and the
degree to which patients are affected by it (Table 4). A total of
10 clinical characteristics are evaluated by a healthcare worker
and graded from absent (score 0) to severe (score 3), with a
total of 30 points attributable. It was developed to assess the
progression of CVD and also to give additional weight to more
severe clinical disease (C4eC6).115,116
The VCSS provides a more accurate measure of the
severity of disease and the effect on the patients’ day to
day activities. Although it is used as a severity score, it has
also been found to be a useful screening tool because of its
correlation with severity on imaging.117,118 It has been used
and evaluated in different studies, and appears to be
appropriate for measuring changes after surgery, although it
may not be appropriate in studies investigating the use of
stockings, as the scoring system takes this into account.119
The VCSS has been employed minus the stocking compo-
nent (VCSS-S) for example, in the assessment of mechanical
suppression of angiogenesis in varicose vein surgery.120
2.2.2.2. Venous Segmental Disease Score: pathophysiology
and anatomy. The Venous Segmental Disease Score (VSDS)
takes into account the anatomical and pathophysiological
mechanisms involved in the presentation of CVD
(Table 5).115,121 VSDS accounts for anatomical location and
nature (reﬂux or obstruction) of venous disease, providing a
global assessment of pathophysiological disease severity. It
relies on duplex scan assessment of the superﬁcial and deep
venous systems and provides a score out of 10 for reﬂux or
obstruction. Although the pathophysiology and abnormalModerate (2) Severe (3)
Daily, interfering with, but not
preventing regular daily activities
Daily limiting most regular
daily activities
Conﬁned to calf or thigh Involve calf and thigh
Extends above ankle but below
knee
Extends to knee or above
ea Diffuse over lower third of calf Wider distribution
(above lower third of calf)
ea Diffuse over lower third of calf Wider distribution
(above lower third of calf)
ea Involving lower third of calf Involving more than lower
third of calf
2 >2
>3 months but <1 year >1year
Diameter 2e6 cm Diameter >6 cm
gs Uses stockings most days Full compliance with
stockings
Table 5. Venous Segmental Disease Score (VSDS).
Reﬂux Obstruction
½ Small saphenous




2 Calf veins, multiple (Posterior Tibial only ¼ 1) 1 Calf veins, multiple
2 Popliteal vein 2 Popliteal vein
1 Femoral vein 1 Femoral vein
1 Profunda femoris vein 1 Profunda femoris vein
1 Common femoral vein and above 2 Common femoral vein
1 Iliac vein
1 Inferior Vena Cava
10 Maximum reﬂux score 10 Maximum obstruction score
Management of Chronic Venous Disease 689venous segments can be described accurately using the
advanced CEAP classiﬁcation, VSDS attributes different
scores to different venous segments to indicate the level of
overall impact on venous function.
Reﬂux describes all valves in a speciﬁc segment as incom-
petent. Obstruction describes a total occlusion at a point in the
investigated segment or a >50% stenosis in at least half the
segment. Importantly, traumatic obstruction, ligation, or
excision of deep venous segments count as thrombosis.
However, the same is not true for superﬁcial veins. Perforator
interruption and saphenous ligation/ablation count as a
reduction of the reﬂux score, not as an obstruction score.
VSDS was found to correlate with clinical scores, with the
magnitude of reﬂux correlating with symptom severity.119
2.2.2.3. Venous Disability Score: functional impact. The
Venous Disability Score (VDS) provides a simple measure of
the functional impact of CVD, using a 4 point scale (0e3;
Table 6).115 This evaluates the effect of CVD on daily ac-
tivities. VDS has been validated against the CEAP as a
measure of disease severity, and has been used as aTable 6. Venous Disability Score (VDS).
0 e Asymptomatic
1 e Symptomatic but able to carry out usual activities without
compressive therapy
2 e Able to carry out usual activities only with compression
and/or limb elevation
3 e Unable to carry out usual activities even with compression
and/or limb elevation
Usual activities: deﬁned as patient activities before the onset
of disability from venous diseasemeasure of change following venous surgery.119 As with
VCSS, VDS is designed to complement the CEAP classiﬁca-
tion by providing greater detail on the level of disability
experienced by the patient.
2.2.3. Villalta-Prandoni Scale
The Villalta-Prandoni Scale was described in the 1990s to
classify the severity of post-thrombotic syndrome (PTS), a
complication of deep venous thrombosis.122 Essentially, the
scale consists of ﬁve symptoms (patient rated) and six physical
signs (clinician rated), with each of the 11 factors scored out of
3 (total score out of 33; Table 7). A score of >14, or the
presence of venous ulceration, indicates severe PTS.
TheVillalta-Prandoni Scale is speciﬁc to the post-thrombotic
limb and is a reliable, valid measure of PTS in patients with
conﬁrmed deep venous thrombosis (DVT).123 It also correlates
well with patient perceived health burden and QoL scores. A
drawback of this scale is that it does not take into account
venous claudication or venous ulcer severity, as the presence
of a venous ulcer is given a ﬁxed score irrespective of severity.2.3. Quality of life measures in venous disease
The burden of CVD lies with the patients, with up to 30%
displaying symptoms suggestive of a depressive illness.124
Assessment of QoL in patients with CVD is integral to a com-
plete and thoroughevaluationof their disease status. Evidence
shows that increasing clinical severity correlates strongly with
deterioration in QoL measures, both general and disease
speciﬁc.113 Similarly, clinical improvement correlates with
progression in QoL measures.125 Clinical classiﬁcation systems
Table 7. Villalta-Prandoni Scale.
[severity scoring: none (0), mild (1), moderate (2), severe (3)]. Each
sign/symptom is scored 0e3; scores are added to obtain the ﬁnal
result (maximum of 33).











Severity of post thrombotic
syndrome (PTS)
- No PTS <5
- Mild PTS 5-9
- Moderate PTS 10-14
















Table 9. EuroQoL e 5D.
1. Mobility - No problems
- Some problems
- Bed bound
2. Self care - No problems
- Some problems washing
or dressing
- Unable to wash or dress
3. Usual activities - No problems
- Some problems
- Unable to perform
4. Pain/discomfort - None
- Moderate
- Extreme
5. Anxiety/depression - None
- Moderately
- Extremely
Euro e QoL VAS
Perceived health Visual analogue scale
0 (worst state)e100 (best state)
690 C. Wittens et al.are in place to assess the severity of CVD. QoL tools are
available to assess patient reported outcomes. The ideal QoL
tool should be generally applicable to any disease process,
irrespective of severity, outcome measures, or geographic
location.16 The tool should be valid (i.e. measure what is
intended), reliable (i.e. provide the same measurements for a
single individual despite different conditions), and responsive
(i.e. sensitive to assess change e.g. after treatment). Ideally, it
should also assess all aspects ofQoL, including physical,mental
and social wellbeing. A number of global QoL instruments
exist; however, they lack sensitivity to changing clinical con-
ditions. Health related measures are used instead. A large
number of tools have been developed and are in widespread
use. There have been greater efforts to standardize the use of
QoL assessments in recent years.
Generic and disease speciﬁc instruments measuring health
related QoL in patients with CVD are discussed below.
2.3.1. Health related generic tools
2.3.1.1. SF-36, Medical Outcomes Study 36 Item Short
Form. The SF-36 form is a widely used, generic QoL
assessment tool with both physical and mental domains,
providing a global assessment of patient wellbeing
(Table 8).126 The physical component of this patient
completed questionnaire has been shown to correlate with
venous disease severity. Studies have shown that all sub-
domains of the physical component (physical role, pain,
physical functioning, and general health perception) corre-
late signiﬁcantly with disease severity as measured by the
CEAP classiﬁcation. This is not true for the mental compo-
nent, as correlations with vitality127 and mental health128
are weak and inconsistent.2.3.1.2. EuroQoL, 5D. The EuroQoL group is a multinational,
multicentre, and multidisciplinary network of researchers
dedicated to the measurement of health status. The Euro-
Qol questionnaire was devised in the 1990s with the aim of
developing a standardized, simple, and generic measure of
health for clinical and economic appraisal.129 It consists of a
descriptive part, evaluating ﬁve dimensions (EuroQol e 5D),
and a vertical, visual analogue scale (VAS), recording the
respondent’s self-rated health (EuroQol e VAS).
Together, the EuroQol, 5D and EuroQoL-VAS, provide a
comprehensive measure of health state. This tool is
particularly useful for measuring utility or quality-adjusted
life years (QALYs; a measure of disease burden), and has
been used as a QoL measure in the assessment of patients
with symptomatic varicose veins (Table 9).124
2.3.2. Disease speciﬁc tools
2.3.2.1. Aberdeen Varicose Veins Questionnaire. The
Aberdeen Varicose Veins Questionnaire (AVVQ), is a patient
completed QoL assessment tool comprising 13 questions
with domains including physical symptoms, social effect,
and cosmesis (Table 10).130 Each question is graded in
Management of Chronic Venous Disease 691terms of severity/presence or absence, and the results are
collated into the Aberdeen Varicose Veins Symptom
Severity Score from 0 to 100, where the higher the score,
the worse the QoL.
The AVVQ has been validated as a measure of health
outcome in patients with varicose veins against the SF-36
questionnaire.131 It was found to be reliable, with signiﬁ-
cant association with patient symptoms. Many consider the
responsiveness and sensitivity of the AVVQ to be greater
than generic QoL questionnaires. However, generic QoL tools
allow simpler calculation of health utility (QALYs), which is a
necessity for meaningful health economy comparisons.
2.3.2.2. Chronic Venous Insufﬁciency Questionnaire.
Developed in 1996 in France, the Chronic Venous Insufﬁ-
ciency Questionnaire (CIVIQ) is a 20-item self reporting QoL
tool covering four dimensions: physical, psychological, social
functioning, and pain (Table 11).132 The items are graded on
a 5 point Likert scale.133 The questionnaire has been vali-dated in its French version, as well as in a number of other
languages.134,135
In 2010 psychometric validation was carried out, revali-
dating the questionnaire and providing evidence for itsTable 10. AVVQ.
1. Distribution of veins
2. Duration of pain
3. Duration of analgesia
4. Degree of ankle swelling
5. Use of support stockings
6. Extent of itching
7. Presence of discolouration
8. Presence of rash or eczema
9. Presence of skin ulcer
10. Degree of concern at appearance
11. Inﬂuence on choice of clothes
12. Interference with work/household jobs
13. Interference with leisure
(score 0e100; 0 best, 100 worst)consistency, reliability, and value in assessing changes in
QoL after treatment.136
2.3.2.3. Venous Insufﬁciency Epidemiological and Economic
study. The Venous Insufﬁciency Epidemiological and Eco-
nomic study (VEINES) was an international, prospective
cohort study evaluating the epidemiology and outcomes of
CVD.137 As part of this project, a validated venous disease
speciﬁc QoL and symptom measure was developed (VEINES
QoL/Sym; Table 12).138 The aim of this tool was to provide an
assessment of QoL and symptoms across the range of con-
ditions in CVD (including telangiectasia, varicose veins,
oedema, skin changes, and leg ulcers). Psychometric testing
revealed the questionnaire to be acceptable, reliable, and
valid in four different language versions, as well as demon-
strating correlation with both SF-36 and C class. The VEINES
QoL/Symwas also found to be reliable and valid as a measure
of QoL and symptoms in patients with acute DVT.139CHAPTER 3: DIAGNOSTICS
Introduction
This chapter describes the value of available diagnostic tools
used in patients with CVD. It describes the physical exami-
nation and additional tests including continuous wave [CW]
Doppler, duplex ultrasound [DUS], phlebography, plethys-
mography, venous pressure measurement, and modern im-
aging techniques such as magnetic resonance venography
[MRV] and computed tomography venography [CTV], as well
as describing clinical and radiological diagnostic criteria of
recurrent disease.
In the diagnostic work up the nature of the problem and
the severity of the disease should be determined.
3.1. Clinical examination
3.1.1. History
Scientiﬁc evidence. Patients with varicose veins and/or
signs of CVD should be asked, prior to any clinical or
692 C. Wittens et al.diagnostic investigation, about symptoms suggestive of
venous pathology.140 This applies also to patients with
recurrent varicose veins following intervention, who may
present with characteristic symptoms of CVD. Possible
thromboembolic antecedents should be investigated,
together with any allergy, medication (oral contraceptives
primarily), and concomitant relevant diseases including
heart and renal failure, which may inﬂuence CVD.140 Finally,
the number and timing of pregnancies should be noted.141
A differential diagnosis is very important. Even in the
presence of trunk varices, many lower limb symptoms could
have a non-venous cause.5,1423.1.2. Physical examination
Scientiﬁc evidence. Patients with CVD are examined in a
physiological upright standing position. Both legs should be
examined completely.When signs of severe CVD or secondary
(e.g. post-thrombotic) varices are present, the abdominal re-
gion should be inspected for the possible presence of venous
collaterals. Venous collaterals on the lower abdomen, ﬂanks,
and pubic region are pathognomonic of iliac or ilio-caval
outﬂow obstruction.
Corona phlebectatica paraplantaris should be noted as
this may indicate advanced venous stasis.143
In recurrent disease, it is important to bear in mind the
patient’s pre-operative state and assess any amelioration or
worsening in signs such as skin changes or ulceration.
During physical examination, it is important to consider
alternative pathology such as signs of arterial insufﬁciency,
orthopaedic, rheumatological, or neurological pathology
(muscle pump function). The main circumferences of both
legs should be measured when indicated (e.g. phlebolym-
phedema, suspicion of vascular malformations).
Traditional clinical tests such as Trendelenburg, Perthes, and
others have proven unreliable and have no place in the map-
ping of venous incompetence in general, and of varicose veins
in particular.144,145
3.2. Diagnostic tools
3.2.1. Deﬁnition of reﬂux
Scientiﬁc evidence. In a study using DUS, reﬂux times in the
various venous segments of the lower extremity wereexamined.146 Distinctions were made between the iliac
veins, the femoro-popliteal axis, deep veins in the calf, and
superﬁcial and perforating veins. Both normal subjects and
patients with known CVD were studied and compared,
including the differences between supine and upright ex-
amination by DUS.
When the duration of retrograde ﬂow in patients with
CVD was compared with healthy subjects, there was a sig-
niﬁcant (p < .0001) difference for all segments in the
affected leg. The cut off values deﬁning venous incompe-
tence (reﬂux) during ultrasound examination are set at
retrograde ﬂow longer than 0.5 s in the superﬁcial venoussystem, the deep femoral vein, and the calf veins, longer
than 1 s in the common femoral, femoral vein, and popliteal
vein, and longer than 0.35 s in perforating veins.146
An additional ﬁnding of this study is that an erect posi-
tion is the only reliable way to detect reﬂux.146
Previous international consensus held 0.5 s as a cut off
value in all leg vein segments, but this appears to vary
with the type of venous segment. The present consensus
recommends 1 s as the cut off duration for reﬂux in
femoral and popliteal vein, whereas above 0.5 s is
considered reﬂux in saphenous veins, lower leg veins, and
perforators.146
The GSV, AASV, PASV, thigh extension, and SSV all sit-
uated in their saphenous compartment, are the main su-
perﬁcial conduits to be imaged for morphology and tested
for possible reﬂux, and its segmental distribution.147 Main
thigh or lower leg perforators, mostly on the medial
aspect of the limb, should be examined with diameters
measured at fascia level. Perforators should also be tested
for their inward and/or outward ﬂow during distal calf
compression (systole) and release (diastole).147 Saphenous
diameter should be measured at speciﬁc locations: the
GSV 3 cm below the saphenofemoral junction, at mid-
thigh, at the knee, and lower leg; the AASV 3 cm below
the SFJ and at mid-thigh when still lying in its saphenous
compartment; and the SSV 3 cm below the SPJ.148 The
terminal and pre-terminal valves of GSV must be tested
for their function, as Cappelli demonstrated that GSV
Table 11. CIVIQ e 20.
In the past four weeks, to what extent did your leg
problems interfere with./cause you.
Physical Items 1. Climbing stairs
2. Crouching/Kneeling
3. Walking briskly
4. Doing the housework
Psychological
Items
1. Feeling on edge
2. Becoming tired easily
3. Feeling like a burden to people
4. Needing to take precautions
5. Embarrassment to show one’s legs
6. Being easily irritable
7. Feeling handicapped
8. Having difﬁculty getting going
in the morning
9. Not feeling like going out
Social items 1. Going out in the evening
2. Practicing a sport
3. Travelling by car/bus/plane
Pain items 1. Pain in the ankles or legs
2. Interference with work or daily
activities
3. Interference with sleeping
4. Interference with standing for
a long time
Management of Chronic Venous Disease 693diameter at proximal thigh is strictly related to the pres-
ence or absence of reﬂux at the terminal valve and at the
iliac-femoral valve.149,150
Assessment of venous reﬂux and of perforators is largely
based on DUS. Limitations diminish for the abdominal and
or pelvic veins. Antegrade ﬂow and reﬂux are elicited
through the creation of a pressure gradient, with speciﬁc
manoeuvres (e.g. Valsalva manoeuvre and compression/
release manoeuvre). Patency of the main deep veins of thelower limbs (common femoral vein, femoral vein, popliteal
vein, gastrocnemius veins, peroneal and tibial veins) should
be highlighted, especially when detection of deep vein
thrombosis or its sequelae (post-thrombotic syndrome) is
required.
3.2.2. Handheld continuous wave Doppler
Scientiﬁc evidence. Doppler examination is a non-invasive
procedure using ultrasound information to determine
venous ﬂow. CW Doppler provides no information on
venous morphology, therefore it is unsuitable for the
determination of any anatomical component of any venous
disease. Reliability of CW Doppler examination in detecting
obstruction/reﬂux in deep veins is extremely low in
abdominal and lower leg veins. Research has shown that
pre-operative planning on the basis of CW Doppler alone,
instead of DUS, results in inadequate treatment in a sig-
niﬁcant proportion of patients.151 In a study of 40 patients
it was found that DUS is much more reliable than both
physical examination and CW Doppler, with little difference
in reliability between the last two.152
3.2.3. Duplex ultrasound examination
3.2.3.1. Efﬁcacy. Scientiﬁc evidence. DUS examination is
based on a combination of ultrasound imaging and pulsed
wave Doppler with which information can be obtained on
both the anatomy and the hemodynamic features of the
venous system. Additional colour ﬂow imaging is routinely
employed to quicken and improve DUS accuracy.
Anatomy, valvular incompetence, and venous obstruction
can be easily detected using DUS.153e157 With DUS it is also
possible to investigate the deep venous system in most
segments with adequate accuracy.158 In addition to good
reproducibility, the non-invasive nature of duplex scanning
is a great asset. With the development of this technique,
invasive tests such as phlebography have been reserved for
a few selective indications (see 3.2.5), as well as making
former non-invasive devices such as handheld Doppler
obsolete. DUS examination should be considered as the
gold standard in the diagnosis of CVD.
However, DUS investigation has a lower reliability to elicit
patency, obstruction, or occlusion of deep veins in the lower
leg, whereas a higher accuracy has been reported in the
Table 12. VEINES QoL/Sym.











- Several times a week
- Once a week
- <Once a week
- Never
At what time of day is the problem most intense? - On walking
- At midday
- At the end of the day
- During the night
- At any time of day
- Never
Compared to one year ago, how would you rate your leg problem now? - Much better
- Somewhat better
- About the same
- Somewhat worse
- Much worse
- I did not have a problem last year
Does your leg problem limit you in the following activities?
1. Daily activities at work
2. Daily activities at home (housework)
3. Standing for long periods
4. Sitting for long periods
- I do not work
- Yes, a lot
- Yes, a little
- Not limited at all
During the past 4 weeks, have you had any of the following at work/during your
day as a result of your leg problem?
- Yes
- No
1. Cut down the amount of time you spent at work/doing activities
2. Accomplished less than you would like
3. Limited in the kind of work or other activities
4. Difﬁculty performing the work or other activities
During the past 4 weeks, to what extent has your leg problem interfered with your
normal social activities with family, friends, neighbours or groups?
- Not at all
- Slightly
- Moderately
- Quite a bit
- Extremely






How have you felt over the past 4 weeks as a result of your leg problem?
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Table 12-continued
1. Concern about the appearance of your leg(s)?
2. Irritable?
3. Burden to your family or friends?
4. Worried about bumping into things?
5. Has the appearance of your leg(s) inﬂuenced your choice of clothing?
- All of the time
- Most of the time
- A good bit of the time
- Some of the time
- A little of the time
- None of the time
Management of Chronic Venous Disease 695femoro-popliteal segment.159,160 Transvaginal DUS evalua-
tion of pelvic veins is not yet fully deﬁned.161,162
Additional colour ﬂow imaging resulted in facilitation of
the overall approach to the insonated segment to assess
patency and competence. In the post-thrombotic syndrome,
DUS identiﬁes residual obstruction, persistent occlusion,
and valvular incompetence in the affected segments, with
greater accuracy in the infrainguinal areas. Phlebography or
MRV/CTV have a deﬁnite role in the diagnostic work up of
the veins in the abdominal/pelvic area.
With the introduction of duplex ultrasound, other non-
invasive techniques such as Doppler and plethysmography
(except certain parameters of air-plethysmography) have
lost most of their value, and are no longer used in the
routine evaluation of CVD.
DUS is an ideal tool for follow up. DUS performed 1 year
after surgery focusing on detection of neovascularization,
has a high accuracy in predicting recurrence at the SFJ after
5 years.163 DUS is also used in the pre-operative assessment
of patients undergoing surgery, as recommended by the
clinical practice guidelines of the Society for Vascular Sur-
gery and the American Venous Forum.140
3.2.3.2. Technique. The extent of DUS depends on the
symptoms. In severe CVD, after a deep vein thrombosis or
persistent or rapidly recurrent varicosities, it is important to
fully scan the deep system including the iliac tract. With
primary varicose veins it is sufﬁcient to scan below the groin
in most cases. When pelvic vein incompetence and or
obstruction is suspected, complementary scanning in the
pelvic area is recommended. Alternative methods (e.g. CTV,
MRV, and especially phlebography) are to be used for a
more complete diagnosis and for planning possible
treatment.
The ﬁve major components that deﬁne a complete DUS
examination are: anatomical information, ﬂow visualization
(presence or absence of reﬂux), provocation manoeuvres
for ﬂow augmentation, morphology (patency or oblitera-
tion), and compressibility (thrombosis diagnosis).
Standardized DUS examination to determine reﬂux in
superﬁcial and perforating veins must be performed with
the patient in a physiological standing position with external
rotation of the examined limb in a relaxed position, while
supporting the weight on the contralateral limb. Investiga-
tion of patency of iliac and patency and incompetence of
common femoral veins should be performed with the pa-
tient in supine position, whereas femoral and popliteal vein
segments should be investigated with the patient standingas for competence, although patency also can be elicited in
supine and prone position, respectively.147 Lower leg deep
veins should to be examined with relaxed calf muscles.
High frequency broadband linear transducers are generally
used to investigate the lower limbs, whereas low frequency
broadband curved array transducers are used when investi-
gating deeper veins (e.g. obese patients, abdominal veins).
An appropriate transducer for transvaginal ultrasound may
be used in case of suspected pelvic vein incompetence. An
adequate pulse repetition frequency setting is required to
detect low velocities (5e10 cm/s) and/or reﬂux.147
3.2.3.3. Imaging recurrent disease. Recurrent disease can
be reliably assessed by DUS. DUS can provide the necessary
anatomical and functional information about the nature of
recurrence and is a fundamental component of the assess-
ment of the lower limb after venous intervention.148 Studies
reporting on recurrent varicose veins largely use DUS ex-
amination in their assessment of the venous system.164e167
As recurrent disease will be most likely secondary to inter-
vention in the GSVor SSV systems, DUS is an appropriate, low
risk imaging modality to assess these patients.
It is important to understand that DUS examination diag-
nosed recurrence may be present in the absence of clinical
recurrence. Patients may have recurrent reﬂux identiﬁed
during DUS examination that does not cause any clinical
symptoms. The 5 year recurrence rate on DUS has been re-
ported at 64%, with a clinical recurrence rate of 4%.168,170
3.2.4. Plethysmography and venous pressure measure-
ments
3.2.4.1. Strain-gauge plethysmography. Scientiﬁc evi-
dence. This was ﬁrst described in 1953 by Whitney, and then
developed as a method for indirect venous function mea-
surement.171 It was then developed for DVT detection or for
quantiﬁcation of post-thrombotic syndrome (PTS). By deter-
mining a pressure volume relationship, this technique can
translate the volume reduction into a pressure decrease.172
3.2.4.2. Photoplethysmography. Scientiﬁc evidence. The
principle of photoplethysmography (also known as light
reﬂection rheography), in which the transmission of light
reﬂection in the subdermal venous plexus is detected as a
measure of the change of blood volume in the skin, was
described in 1937 by Hertzman.173 This technique was
initially used for arterial research, but adapted by Abra-
mowitz in 1979 for venous applications.174 In the 1980s,
Wienert and Blazek developed the technique towards a
standardized digital form.175,176
696 C. Wittens et al.The main parameter of venous plethysmography is the
reﬁll time. There is a good correlation between the reﬁll
time and direct venous pressure measurement and photo-
plethysmography.173,177 However, there is no good rela-
tionship between the reﬁll time and the degree of venous
disease.178,179
3.2.4.3. Air-plethysmography. Scientiﬁc evidence. Using
air-plethysmography (APG), volume changes can be
measured, with venous ﬁlling index (VFI) being the most
important parameter.180,181 Also reﬂux quantiﬁcation and
ejection fraction have been assessed and APG parameters
give an overall evaluation of the functional impairment of
the limbs as to venous obstruction/valvular incompetence,
quantifying calf pump dysfunction as well.85
Since the advance of DUS and other alternative methods,
plethysmographical examination techniques have been
considered of less importance in routine investigation, and
they are no longer considered as stand alone diagnostic tools
in patients with CVD. Plethysmography may be considered for
assessment of quantitative parameters related to venous
function for research purposes and post-treatment follow up.
3.2.4.4. Foot volumetry. Foot volumetry is performed in the
standing position by immersing the leg in a container with
water.182 The expelled volume (EV) in mL and the reﬁlling
rate (Q; mL/100 mL  minute), as well as the total foot
volume (mL), are measured. It has been used to assess
compression treatment in venous insufﬁciency and to pre-
dict results of interventions on the superﬁcial venous sys-
tem in case of venous ulceration.3.2.5. Phlebography
Scientiﬁc evidence. The indication for using phlebography in
CVD patients with varicose veins has decreased signiﬁcantly
with the advent of DUS. In the evaluation of superﬁcial,
perforating, and deep vein incompetence, DUS is at least as
reliable as phlebography.155,156 However, in the diagnosis of
pelvic vein obstruction or incompetence (gonadal veins,
iliac veins) and of vascular malformations, when alternative
imaging techniques are inconclusive, phlebography can
represent a necessary investigation.
In the presence of vascular malformation, complex post-
thrombotic cases, or cases of complex recurrent varicose
veins, phlebography may help to elicit possible abdominal
and/or pelvic vein involvement.
3.2.6. Other imaging methods
3.2.6.1. Scientiﬁc evidence. Both CTV and MRV have
evolved signiﬁcantly in recent years and it is now possible to
obtain detailed three dimensional reconstructions of the
venous system.183e188 Ilio-caval and pelvic venous pathol-
ogy (post-thrombotic obstruction, venous compression/
stenosis like Nutcracker syndrome or May-Thurner syn-
drome and pelvic varicocele) can be reliably identiﬁed.189e
193 However, there is insufﬁcient scientiﬁc evidence to
adequately judge the true effectiveness of both techniques
for visualization of the venous vasculature given the het-
erogeneity of the published studies. Furthermore, in vari-
cose vein disease the use of CTV and MRV should be limited
to the speciﬁc indications mentioned above.
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tion of intravenous contrast in both MRV and CTV exami-
nations may be contraindicated. A disadvantage of the MRV
examination is that the acquisition time is signiﬁcantly
longer compared with CTV. Unlike MRV, however, CTV in-
volves exposing the patient to radiation. Both techniques
can be used to diagnose deep venous obstruction, but MRV
has the advantage of displaying more heterogenic infor-
mation of intravascular abnormalities, which may be useful
in determining the therapeutic (endovascular) options.183
The decision of whether to perform MRV or CTV is still
mainly dependent on the local expertise in performing and
evaluating these studies.
Complementary to the aforementioned techniques,
intravascular ultrasound (IVUS) is suitable for deter-
mining ilio-caval venous compression.169,194e198 To
assess chronic venous obstruction or incompetence and
for planning a deep venous reconstruction, DUS exami-
nation, CTV or MRV, ascending and descending phle-
bography and in selected cases IVUS have to be
performed. In addition, venous pressure measurement
can be performed to clarify whether the venous collat-
erals are capable of adequately reducing ambulatory
venous hypertension.154,169,194,199e203CHAPTER 4: TREATMENT OPTIONS IN CHRONIC
VENOUS DISEASE
Introduction
A variety of treatment methods are currently available for
patients with CVD, and these are presented in detail below.4.1. Dressings for venous ulcers
Scientiﬁc evidence. A large number of types of wound
dressing are in current use for venous ulcers. Two separate
Cochrane reviews concluded that alginate and foam dress-
ings do not increase venous ulcer healing rates and that
more research is needed before recommending them.204,205
Similar results have been shown for hydrocolloid dress-
ings.206 There is also no evidence to support the routine use
of silver donating dressings beneath compression for
venous ulceration.207
Another Cochrane review showed that the use of topical
cadexomer iodine was more effective than standard care in
achieving complete healing when added to compression
therapy (risk ratio 6.7, p ¼ .011). However, use of compres-
sion with povidone iodine versus hydrocolloid dressings was
equivalent in achieving complete wound healing.208
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to achieve better ulcer healing compared with alginate
dressings and the zinc oxide stockingette.209 Further
research is needed to investigate the role of zinc dressings
on wound healing.
Local allergic side effects might limit the use of topical
antimicrobial dressings.4.2. Compression therapy
Introduction. Compression therapy, despite signiﬁcant im-
provements in dressing materials and other methods, re-
mains the cornerstone of conservative treatment. This is
because of its ease of use, non-invasive nature, and also
efﬁcacy in managing venous hypertension, the main path-
ophysiological mechanism of CVD.
The most common forms of therapeutic leg compression
are elastic stockings, including tights, non-elastic and elastic
bandages (short and long stretch), and intermittent pneu-
matic compression. The mechanisms of action include
compression of superﬁcial and deep veins and improvement
of the muscle pump function, both leading to reduction of
ambulatory venous pressure and reduction of oedema.4.2.1. Chronic venous disease without ulceration (C0eC4)
Scientiﬁc evidence. Elastic stockings in the form of graduated
compression have been the cornerstone of conservative
management of CVD C0eC4 for decades. They compress
varicose veins, reduce venous reﬂux, and improve calf muscle
pump function. More recently it has been shown that pro-
gressive graduated compressive stockings (higher pressure at
the calf comparedwith the ankle) aremore effective than the
usual degressive graduated compressive stockings (higher
pressure at the ankle) in improving pain and lower leg
symptoms. Furthermore, they were easier to apply.210 These
beneﬁcial effects might be related to the observation that
progressive graduated compressive stockings have a more
pronounced effect on venous pumping function thangraduated elastic compression.211 Higher pressure at calf
level duringwalking also seems to be the reasonwhy inelastic
bandages are haemodynamically more effective than stock-
ings, which give way during muscle contraction.212 Despite
the popularity of elastic stockings, evidence of their efﬁcacy is
unclear, based on the lack of randomized controlled trials for
both superﬁcial venous incompetence and the post-
thrombotic leg.213,214However, there is ample lower quality evidence based
on non-RCTs and clinical experience, to suggest their use
because they improve patient symptoms213 and they
improve patients’ QoL.215 In general, there are issues
putting on and removing elastic stockings, especially in
the elderly, which along with the sensation of warmth
and deterioration of pre-existing pruritis associated with
venous eczema, could account for the suboptimal patient
compliance.216 Additional issues include potential skin
damage, and contraindications to use including periph-
eral arterial disease. Also, elastic stockings require proper
ﬁtting and, to remain effective, should be replaced at
intervals of 3e4 months, according to the manufacturers’
instructions.4.2.2. Venous ulceration (C5eC6)
4.2.2.1. Venous ulcer healing. Scientiﬁc evidence.
Compression bandages have been shown to improve healing
rate of ulcers compared with standard care without
compression.217e219 An alternative to traditional bandaging
is non-elastic compression, including the Unna boot (a
compression dressing impregnated with zinc oxide paste)
and a non-elastic compression system based on adjustable
Velcro bands that can be changed and adjusted daily elimi-
nating odorous secretions.220 However, involving an elastic
component in a bandage system seems more effective in
terms of wound healing than when it is not involved.219
In a RCT, sustained compression of at least 40 mmHg with
a four layer compression bandage over a week has been
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compression.221 However, other bandage types applying
sustained high pressure compression (including two or
three layer compression bandages, the Unna boot, paste
bandages, or high compression stockings) have been shown
by the vast majority of studies to be equally effective as
four layer compression bandages.222e230 This is likely to be
the result of improved properties of the former materials
(including adhesiveness of bandaging material allowing it to
be kept in place) and familiarity of use.231 However, use of a
four layer bandage does result in faster healing of ulcers
compared with a short stretch bandage.219
Until several trials with conclusive results favouring one
particular compression system are published, the initial
treatment modality should be the one with which the
person applying the compression is most familiar. However,
the differential properties of the various bandage types
deserve further investigation.2324.2.2.2. Venous ulcer recurrence. Scientiﬁc evidence.
Compression is important to prevent ulcer recurrence and
most beneﬁt is seen from high compression; however, this
is more likely to be associated with patient intolerance.233
Following healing of the ulcer, compression bandages
should be replaced by elastic stockings. The latter could be
the deﬁnitive treatment, particularly in patients with deep
vein occlusion or gross incompetence not amenable to
widely accepted surgical or interventional solutions. Pa-
tients should wear the highest level of compression that is
comfortable, preferably 25e35 mmHg at ankle level.234 In
the ESCHAR trial, compression in the form of four layer
bandaging was shown to be equally effective with surgery
and compression in achieving healing of venous ulcers,
although long-term effects were less durable in terms of
recurrence compared with surgery.235
Another trial reached similar conclusions but surgery
combined with ambulatory compression therapy was more
durable than compression alone in patients with medial
and/or recurrent ulceration, who should receive superﬁcial
and perforating vein surgery.2364.2.3. Intermittent pneumatic compression for venous
ulceration
Scientiﬁc evidence. Intermittent pneumatic compression
(IPC) improves venous ﬂow signiﬁcantly in patients using
elastic bandages,237 while, in combination with elastic stock-
ings, it has been shown to increase healing rates and overall
healing of venous ulcers compared with elastic stockings
alone.238 Three subsequent trials either failed to demonstrate
any beneﬁt when IPC was used in conjunction with compres-
sion,239 or this was marginally signiﬁcant.240,241 This raises
concerns regarding its efﬁcacy.242 However, in a trial that
included patients with venous ulcers not using background
compression, rapid IPC (one short compression period of 6.5 s
three times a minute) healed 86% of venous ulcers compared
with 61% with slow IPC (one long compression period of 90 s
every 3 minutes) at 6 month follow up, p ¼ .003.243
It has been proposed that IPC should be provided only for
patients with refractory oedema and signiﬁcant leg ulcera-tion after a 6 month treatment course, with standard
methods such as compression stockings, has failed.244
IPC is also effective in CVI and higher compression
pressures have been reported to be associated with greater
leg volume reduction in patients with chronic venous
oedema.245 IPC is able to provide symptom relief in patients
with PTS.246,247
More research is needed to establish which kind of
compression may, in combination with IPC, be most bene-
ﬁcial in ulcer healing. Also the IPC impact should be studied
in relation to ulcer characteristics (duration since onset,
surface area and depth).
4.2.4. Compression after venous intervention
Scientiﬁc evidence. A meta-analysis has shown that short
duration (about a week) compression after varicose vein
surgery is as good regarding post-operative pain, leg vol-
ume, incidence of complications and absence from work as
longer use (3e6 weeks) of compression.248 Additionally,
after EVLA, use of high compression proﬁle (35 mmHg)
elastic stockings for 7 days signiﬁcantly reduced pain and
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compared with use for 2 days.249
Similarly, after foam sclerotherapy, compression
bandaging for 24 hours and thromboembolus deterrent
stockings for a fortnight were equivalent to 5 days of
bandaging, conﬁrming results shown by a previous study
with a similar design.250,251 However, use of low compres-
sion proﬁle elastic stockings after foam sclerotherapy of
larger veins had no effect on efﬁcacy, side effects, and
satisfaction scores compared with a control group without
compression.252 Following superﬁcial vein surgery for
venous ulceration, especially after GSV stripping to the knee
or residual deep or superﬁcial venous reﬂux, continuation
of compression could be considered.
Use of elastic stockings (23e32 mmHg) for 3 weeks after
sclerotherapy for leg telangiectasias, compared with no
such intervention, was associated with an improved efﬁcacy
as determined by clinical vessel disappearance.253
Further studies are needed to establish the duration of
compression as well as the type of compression (full length
or knee length) following superﬁcial vein surgery for
ulceration.4.3. Physiotherapy, leg elevation, and leg massage
4.3.1. Physiotherapy for leg ulceration
Scientiﬁc evidence. A reduced range of joint mobility has
been described in CVD, correlating with the disease severity
(CEAP clinical class) and haemodynamic changes on air
plethysmography.254 A ﬁxed ankle joint and reduced range
of movement have been shown to be independent pa-
rameters associated with non-healing of venous ulcers,
indicating that these ﬁndings are related to the impairment
of the calf muscle pump.255 Furthermore, calf muscle pumpfunction and dynamic calf muscle strength can be improved
with exercise,256,257 as can the range of ankle movement.258
One small underpowered RCT showed a non-signiﬁcant
trend for reduced ulcer size with physiotherapy compared
with no intervention.259 Another RCT showed that the
group of patients who received lifestyle counselling had
increased physical activity and reduced wound days
compared with the control group, but a larger RCT of 40
patients failed to demonstrate any effect of home based
progressive resistance exercise on ulcer healing
parameters.260,261
Properly powered studies are needed on the effect of
supervised exercise on healing rates of venous ulcers.
4.3.2. Leg elevation
Scientiﬁc evidence. Leg elevation has been used for a long
time and is still recommended to patients to ameliorate
venous stasis, provide symptomatic relief, reduce leg oedema,
and promote healing of ulcers in patients with CVD.262,263
Leg elevation in patients with CVD classiﬁed as C3eC6
has been shown to reduce leg volume and venous pressure,
and to enhance the microcirculatory ﬂow velocity in lip-
odermatosclerotic skin.264e266In the past, elevation has been used as the main measure
to heal venous leg ulcers or as an adjunctive measure in
patients wearing elastic bandages.267,268 It is still practiced
in combination with antibiotics and debridement in cases of
infected ulcers where compression cannot be tolerated
because of pain associated with cellulitis in the surrounding
areas. In a retrospective study, elevation was a statistically
signiﬁcant predictor of ulcer free survival among other
variables, while in a structured education programme, pa-
tients who were allocated to the study group spent more
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ulcer recurrence rate.269,270 Others reported that in the
presence of compression, there was no correlation between
median leg elevation per 24 hours and percentage decrease
in ulcer size.265 Although still recommended, treatment
cannot rely on this otherwise simple advice, because pa-
tient compliance is poor and ulcer recurrence is extremely
common even after a period of prolonged hospitaliza-
tion.271,272 Finally, leg elevation has been used before
bandages are applied and could also be used to reduce leg
swelling before elastic stockings are ﬁtted.273
Prospective, randomized studies should be performed
investigating the role of leg elevation in healing venous leg
ulcers. But even with the lack of strong evidence, practice
and physiology suggest that leg elevation is helpful.4.3.3. Leg massage
Scientiﬁc evidence. This method can be part of a multi-
component regimen aimed at reducing tissue oedema by
applying deep massage around the ulcer area, before formal
compression is applied, or as an adjunct. Leg massage entails
a form of light massage over elastic compression with a
stocking.267,274 Further studies are necessary to assess the
role of leg massage in patients with venous oedema, but IPC
has largely replaced leg massage.4.4. Medical treatment
Introduction. Medical treatment has been used for de-
cades, but its place as a treatment modality for CVD is a
topic of continuing debate. Venoactive drugs are widely
prescribed in some countries but are not available in others.
They can be classiﬁed into two groups: natural and syn-
thetic drugs, such as naftazone and calcium dobesilate,
respectively. The main modes of action of venoactive drugs
are to decrease capillary permeability, diminish release of
inﬂammatory mediators, or improve venous tone. Non-
venoactive drugs like pentoxifylline, reduce white cell acti-
vation, and acetylsalicylic acid inhibits platelet function and
also has an anti-inﬂammatory effect.
4.4.1. Chronic venous disease without ulceration (C0eC4)
Scientiﬁc evidence. In 2005, a Cochrane review of 110
publications was published with 44 studies (CEAP classi-
ﬁcation C0eC4) considered valid. This review concludedthat there was insufﬁcient evidence to support the use of
all venoactive drugs in the treatment of CVD. However, it
also showed that micronized puriﬁed ﬂavonoid fraction
(MPFF) was the most effective at reducing symptoms of
oedema and restless legs. Calcium dobesilate reduced
cramps and restless legs. MPFF helped in healing
venous ulcerations and was also useful in treatment of
cramps and swelling. Rutosides decreased venous
oedema.275,276
A Cochrane review of 17 randomized controlled trials
(RCTs) showed that horse chestnut extract (HCSE) was
effective at decreasing oedema, pain, and itching.277
Numerous studies have been conducted especially with
MPFF, showing that these products lead to improvement
of symptoms by increasing the venous tone.278e282 TheRELIEF study included 5,052 CVD patients with clinical
class C0 to C4. They were divided into two groups: with
and without reﬂux. All patients received MPFF over 6
months. Assessment was made of presence and/or
severity of pain, heaviness, sensation of swelling, and
cramps in lower limbs. Oedema was measured using the
Leg-O-Meter. In both treatment groups, MPFF signiﬁcantly
reduced symptoms and signs, and reduced ankle
oedema.125Another RCT compared MPFF with placebo and could
only show a difference in night cramps without changing
other symptoms of CVD.283
Calcium dobesilate is a synthetic venoactive drug
which has been evaluated in a few RCTs and one meta-
analysis published in 2004. A recent large RCT with 509
patients could not show a difference between its study
groups.284 However, a double blind, placebo controlled
trial showed that calcium dobesilate reduces leg oedema
and improves the symptoms of objectively diagnosed
CVD independent of the concomitant usage of
compression stockings.285
The effect of Red vine leaf extract was evaluated in a
prospective randomized trial including 248 patients. Efﬁcacy
endpoints were changes in limb volume determined by
water displacement volumetry, clinical CVD symptoms
assessed on a visual analogue scale and global efﬁcacy
evaluations. Red vine leaf extract reduced lower limb
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placebo.286
4.4.2. Venous ulceration (C5eC6)
Scientiﬁc evidence. A Cochrane database review showed
that pentoxifylline is effective as an adjuvant therapy to
compression, but it also appeared to be effective in the
absence of compression.287 Other studies showed an
accelerating healing time when patients were treated with
pentoxifylline,288,289 in addition to wound care.290
Other products, like acetylsalicylic acid and oral zinc, are
not routinely recommended for the promotion of healing
venous leg ulcers.291e294 Some studies showed an acceler-
ation of healing in a patient group treated with acetylsali-
cylic acid, but these were small studies and there was largevariation in the number and size of ulcers. Further research
is necessary on this subject.291e293
The effectiveness of routine use of systemic antibiotics
for venous ulcers could not be demonstrated in a Cochrane
review based on 25 RCTs.208 However, in light of the
increasing problem of bacterial resistance to antibiotics,
current guidelines recommend that antibacterial prepara-
tions should only be used in cases of clinical infection and
not for bacterial colonization.
There is some evidence that sulodexide can support ulcer
healing in combination with compression therapy.295
Although it was thought likely that HCSE would attenuate
the pathogenesis of venous insufﬁciency and, in turn,
facilitate venous ulcer healing, a study by Leach did not
support this.296 A possible reason is that reducing oedema
alone is insufﬁcient to treat venous ulcers.
The time to complete ulcer healing was compared in a
study of patients taking MPFF versus placebo.297 There was
a signiﬁcant reduction in healing time in the treated group
compared with the placebo group. Other symptoms, like
heavy sensation of the legs, were evaluated and were also
shown to be reduced. Other studies have conﬁrmed theseﬁndings.298,299 However, according to a Cochrane review,
the studies mentioned above showed shortcomings in
terms of blinding and allocation.300
In 2005, a meta-analysis of ﬁve RCTs was performed (723
patients with venous ulcers). This showed that at 6 months,
the chance of healing certain subtypes of ulcers was 32%
higher in patients treated with MPFF as an adjunctive treat-
ment in comparison with conventional therapy alone.301
A more recent review concluded that in prospective
randomized studies, MPFF and other ﬂavonoid de-
rivatives, and pentoxifylline have demonstrated clinical
beneﬁts in patients with CVD (clinical class C4eC6).284
Therefore pharmacotherapy should be part of a range
of treatment options in the modern management of
patients with CVD.4.5. Sclerotherapy
Introduction. Sclerotherapy involves injection of dilated
veins, including major reﬂuxing trunks or tributary varicos-
ities, venules, or telangiectasias, with liquid or foam
chemical agents to damage the endothelium and eventually
ablate the veins.
Scientiﬁc evidence. A number of chemical agents e scle-
rosants - with a variety of mechanisms of action have been
used to damage and denude the vessel endothelium,
including polidocanol, sodium tetradecyl sulphate (STS),
morrhuate sodium, glycerin, and hypertonic saline, either
as pure agents or in the form of foam, in increasing con-
centrations according to the size of vein being treated.
Some of these have been mixed with lidocaine to reduce
pain during injection.302,303 Post-procedural compression is
an integral part of this type of treatment, which can be
used to treat the entire spectrum of reﬂuxing superﬁcial
veins, including the saphenous veins, and telangiectasias
with a great degree of efﬁcacy and safety.304 The reader is
referred to section 4.2.4. for further information. However,
patients should be informed of possible side effects (such
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and also allergic reactions) and complications (such as deep
vein thrombosis, pulmonary embolism, or cerebral embolic
event for foam sclerotherapy in the presence of a right to
left cardiac shunt).305,306
Liquid sclerotherapy is more effective than placebo in-
jection for telangiectasias and reticular and/or varicose
veins.307,308 However, in two Cochrane reviews, there is no
evidence suggesting superior efﬁcacy of any one sclerosant
over another.309,310 Lower concentrations of the sclerosant
agent are used for smaller veins. In addition to effective-
ness,307,311 sclerotherapy is less time consuming and is an
easily repeatable treatment. It provides faster recovery with
less pain and is relatively inexpensive compared with sur-
gery or endovenous thermal ablation (EVTA). However,
varicose vein recurrence, as high as 90% after 6 years,312
and the need for additional treatment (more often
compared with surgery) are inherent major problems,312,313
as summarized also by a Cochrane review.314 This is true not
only for the major saphenous trunks, but also for varicose
tributaries if the source of incompetence has not been
eliminated.315 On the other hand, good long-term results in
the primary treatment of isolated varicose veins, not
associated with saphenous vein incompetence have been
demonstrated.312 Treatment of recurrent varicose veins
following surgery is another indication, by avoiding the
morbidity (40% in one study) associated with redo
surgery.316Foam sclerotherapy, usually guided by DUS (ultrasound
guided foam sclerotherapy, UGFS), has been shown to be
more effective than liquid sclerotherapy because of the
enhanced sclerosing properties of the foam form of the
sclerosant.317e320 Foam sclerotherapy has been used asan adjuvant treatment of varicose tributaries following
endovenous ablation of the main reﬂuxing trunk,321 or
high ligation (HL),322 or to treat recurrent varicose
veins.323,324 It is also widely used to treat telangiectasias
and reticular veins, although there is no evidence that
foam sclerotherapy is better than liquid sclerotherapy in
this setting.
UGFS is characterized by a higher recanalization rate
when treating veins larger than 5e7 mm in diameter.325e327
Foam sclerotherapy is associated with a higher recanaliza-
tion rate and similar results in terms of symptoms and QoL
assessment when compared with surgery, laser or radio-
frequency endovenous ablation for treating GSV reﬂux.328e
331 Foam sclerotherapy proved signiﬁcantly cheaper329 and
it may be considered an attractive minimally invasive
alternative to surgery to treat superﬁcial incompe-
tence,332,333 particularly in elderly and frail patients and
especially in those with venous leg ulcers.334,335 Repeat
treatment may be considered an integral part of UGFS in
some of the treated patients and the additional cost
incurred must be integrated into the global cost when it is
compared with the other techniques (surgery or thermal
ablation). Foam sclerotherapy is becoming an increasingly
popular choice in the management of patients with recur-
rent varicose veins.315,324,332 Long catheter foam sclero-
therapy has been introduced recently and its short-term
efﬁcacy is equal or superior to the usual UGFS for GSV
reﬂux.336e339 Long-term results are awaited.4.6. Transcutaneous laser
Introduction. Surface transcutaneous laser (TCL) has been
used for the treatment of telangiectasias and reticular veins
since the 1970s. The mechanism behind this treatment is to
704 C. Wittens et al.cause endothelial injury of the vein by heating the hae-
moglobin and eventually to obliterate the lumen. The
advent of laser technology with delivery of sufﬁciently
controlled energy has enabled achievement of pan-
endothelial necrosis without affecting more superﬁcial
structures such as the epidermal layer. High intensity pulsed
light therapy, which was introduced in 1990, represents a
further development in the ﬁeld as it allows treatment of
reticular veins by emitting a spectrum of light rather than a
wavelength to obliterate the vein.
Scientiﬁc evidence. TCL is an effective treatment for tel-
angiectasias and reticular veins, although not capable of
making them to disappear completely.340 Laser light is
emitted from the laser equipment and transmitted through
the skin to the targeted vessel, where it is selectively
absorbed by the oxyhaemoglobin and converted to thermal
energy leading to heating of the telangiectatic vein, coag-
ulation, and vessel destruction. Different settings of laser
are used for blood vessels of different diameter and skin
type and/or colour.341,342
TCL is less effective than sclerotherapy at managing leg
telangiectasias, requires more treatment sessions,343,344 and
is more expensive. However, particular indications include: 1.
known allergy to sclerosant solutions, 2. needle phobia, 3.
telangiectatic matting after sclerotherapy, 4. failure of
sclerotherapy,345 and 5. vessel size less than 0.5 mm.
Recent technical modiﬁcations have been reported to
signiﬁcantly improve the efﬁcacy of TCL.346,347 Indocyanine
green (ICG)-augmented diode laser therapy has been shown
to be superior to pulsed dye laser and the diode laser
without ICG.346 Similarly, improved results have been
demonstrated in combination with sclerotherapy.348
More studies are needed to establish which telangiectatic
veins, and at what site in the lower limb, are better
managed with TCL. Also, the role of elastic compression
after TCL should be further investigated.4.7. Endovenous treatments
Introduction. Endovenous techniques in the treatment of
saphenous vein incompetence have become very popular as
a minimally invasive alternative to classical surgery (HL and
stripping). In countries where reimbursement is available,
the vast majority of patients are treated endovenously. It
was Carlos Boné in 1999, who ﬁrst treated patients with
endovenous laser.349 In the past 10 years, endovenous
techniques have evolved quickly and performance has
improved.
The two most frequently used techniques are endove-
nous laser ablation (EVLA) and radiofrequency ablation(RFA). Another endovenous thermal ablation (EVTA) tech-
nique is steam ablation.350 Other more recently introduced
techniques are mechanochemical ablation (MOCA)351 and
injection of cyanoacrylate glue.352
The use of EVTA (EVLA, RFA, Steam) techniques requires
injection of tumescent liquid around the target vein. The
purpose of this is to protect the perivenous tissue from the
heat created during treatment. The tumescent liquid acts as
a heat sink.353 Other purposes of the tumescent liquid in-
jection are to create spasm of the vein and to obtain local
compression and anaesthesia. The new non-thermal abla-
tion techniques (MOCA and glue injection) can be per-
formed without injection of tumescence during the
ablation.
The scientiﬁc evidence for cyanoacrylate glue injection is
too little to warrant further attention in this chapter because
of the lack of publications. Steam ablation seems to give
results comparable with other thermal ablation techniques at
1 year follow up,354 but more studies are necessary to
conﬁrm those results in the medium and long term.
4.7.1. Endovenous thermal ablation
Introduction. To evaluate the two most commonly used
EVTA techniques, EVLA and RFA, six meta-analyses,355e360
31 RCTs,328,361e390 six non-randomized comparative clin-
ical trials,391e396 seven prospective clinical trials,397e403 and
one technical review article were selected.404
4.7.1.1. Great saphenous vein. Technique. The technique is
similar for all EVTA methods. The procedure is performed
percutaneously with ultrasound guidance. A laserﬁbre or
RFA catheter is inserted and positioned 1e2 cm distal to
the SFJ, and tumescent liquid is injected around the
saphenous vein. A very dilute solution of local anaesthetic
combined with bicarbonate and epinephrine is used for this
purpose. It is important to empty the vein of blood as
much as possible. While withdrawing the catheter or ﬁbre,
energy is emitted intraluminally to cause irreversible ther-mal destruction of the endothelium of the vein wall.
Compression post intervention is recommended (see sec-
tion 4.2.4.), but the duration of compression is not clearly
deﬁned.405,406
Effectiveness. Occlusion rates of EVLA vary between 77%365
and 99%362 at 1 year. Compared with surgery (HL and
stripping), most studies report no signiﬁcant difference in
varicose vein recurrence (clinical) or recurrent reﬂux (ac-
cording to DUS) after treatment.328,356,364e366,368e370,391
Other studies report a higher recurrence rate after sur-
gery (20% vs. 4% at 1 year)362 or after EVLA (7.4% vs. 0% at
2 years).363 Neovascularization at the SFJ is an important
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seen more commonly after surgery, although this was not
signiﬁcantly different,359 compared with EVTA.366,372
Compared with RFA, surgery seems to be more efﬁ-
cient373,376 orequally effective.371,372 In cases in which sur-
gery was more efﬁcient, RFA was performed using the older
“Closure Plus” catheter (VNUS Med Tech, San Jose, CA,
USA). Meta-analyses show that RFA and EVLA are as
effective as surgery in the treatment of GSV incompe-
tence.355,357,359 The ﬁrst published meta-analysis on EVTA
reports superior results of EVLA compared with surgery and
RFA.355 This study, however, only includes trials using either
EVLA with lower wavelength or RFA with the “Closure Plus”
catheter, and uses heterogeneous deﬁnitions of treatment
failure.
Safety. No difference in safety including the risk of venous
thromboembolism could be determined, comparing EVTA
and surgical treatment for saphenous vein
incompetence.367,391
The reported incidence of DVT varies between 0.2% and
1.3% in EVTA, and seems to be higher in patients treated
with RFA compared with EVLA.357 The latter meta-analysis
mainly included the old RFA techniques and EVLA with
bare tip ﬁbres and lower wavelength. Development of
thrombus extension at the SFJ (often called endovenous
heat induced thrombosis) can be found in a limited
number of cases. Case series report a frequency varying
between 0.3% and 7.8% of patients after EVTA.395,397e399
When thrombus extends into the common femoral vein
treatment by anticoagulation (AC) is advised. Pulmonary
embolism was reported in 0.0% to 3% after EVLA.395,398
Nevertheless, the role of routine use of pharmacologic
prophylaxis remains uncertain and more studies are
necessary.
Thrombo-prophylaxis can be prescribed for high risk pa-
tients (previous venous thromboembolism, documented
thrombophilia, obesity, immobilized patients, patients with
neoplasm, and older patients).407,408 However, risk factors
should be weighted for each individual patient using a
speciﬁc risk assessment score such as the Caprini score.409
Patients can be treated in an outpatient setting under
local tumescent anaesthesia, which permits early ambula-
tion reducing the risk of possible thromboembolic
complications.
Side effects. Post-operative complications in EVTA are
limited. Reported complications are thrombophlebitis
(7%),359 thermal skin injury (<1%),359 bruising, hyperpig-
mentation (5%),359 paresthesia (1e2%),364,369 and haema-
tomas (0e7%).364,369,374,378 Compared with EVTA, surgically
treated patients more frequently develop complications,
such as wound infection (2e6% for surgery vs. 0% for
EVTA)356 and haematomas (5% for surgery vs. 2% for
EVTA).359 Patients treated with EVTA have, on average, less
pain compared with patients treated surgi-
cally.356,365,369,374,377,378 Post EVTA as opposed to surgery,
swelling and bruising is reduced.391 This results in quicker
recovery357,362,375,376 and faster return to normal activ-
ities.364,365,374,378,392 Endovenously treated patients alsoseem to have an equal364,366,367 or better361 QoL after
treatment. The risk of superﬁcial thrombophlebitis appears
to be signiﬁcantly higher (2.3 times) in RFA than in
surgery.356
EVLA: different wavelengths and ﬁbres. To reduce possible
side effects of EVLA (pain, bruising, and haematoma),
higher laser wavelengths have been introduced and
different ﬁbre tips have been developed. Theoretically, light
of lower wavelength lasers (810, 940, 980, 1320 nm) is less
speciﬁcally absorbed by their chromophores (haemoglobin,
water, proteins) compared with the light of higher wave-
length lasers (1320, 1470, 1500 nm).404
The clinical use of higher wavelength lasers should
result in equal occlusion rates (97e100%) and less post-
operative pain.396,402,403 There is only one randomized
clinical trial comparing the use of lower and higher
wavelength lasers.379 Also, most studies reporting results
of higher wavelengths use a lower energy level which
makes it difﬁcult to draw any conclusions regarding
outcome and potential side effects. As the use of a bare
ﬁbre creates unequal energy delivery at the vein wall
resulting in local vein wall perforations and perivenous
tissue destruction, new ﬁbres have been
designed.380,400,404 The purpose of these new ﬁbre designs
is to increase the heated surface area, resulting in lower
energy density. The use of the these new ﬁbres, Never-
touch (AngioDynamics, Latham, NY, USA),393 Radial ﬁbre
(Biolitec, Wien, Austria),394,400 and Tulip ﬁbre (Tobrix,
Waalre, the Netherlands),380 may be safe and effective in
the treatment of saphenous vein reﬂux.
There is a lack of RCTs comparing these ﬁbres with a
standard bare ﬁbre. Only one RCT reports fewer side effects
and an equal occlusion rate using a Tulip ﬁbre compared
with a bare ﬁbre.380
RFA versus EVLA. EVLA and RFA have the same occlusion
rates, but patients treated with RFA have less post-
operative pain and bruising.328,381e384 This can result in
an equal383 or faster328 return to normal activities. In trials
comparing EVLA and RFA, however, the ClosureFast cath-
eter was compared with lower wavelength lasers using a
bare ﬁbre. No trials have been published comparing the use
of ClosureFast with higher wavelength lasers and new ﬁbre
tip design.
Consideration must be given to the fact that in the last
decade the technique and the ﬁbres or catheters used have
improved. The more recently introduced ClosureFast cath-
eter (VNUS Med Tech, San Jose, CA, USA), although no RCTs
are available, seems to be more effective, faster (shorter
operative time), and induces fewer side effects compared
with the older “Closure Plus” catheter.401
UGFS versus EVTA/surgery. The advantage of foam sclero-
therapy is its simplicity. There is no need to inject tumescent
liquid, the treatment is cheap, and easy to repeat if
necessary.
Complications of UGFS include hyperpigmentation,
thrombophlebitis, matting, and pain at the injection site.
Also, some neurologic events, such as visual disturbances,
migraine, and stroke, have been reported.410e413
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of 52.4% and 76.8% respectively.327 Compared with surgery,
UGFS is less efﬁcient328,329,355,356,414,415 but has signiﬁcantly
fewer side effects (less pain, better post-operative QoL, faster
return to normal activities).322,328,329,356,414e416
Occlusion rates of saphenous veins treated with UGFS
seem to be inferior to those of veins treated with
EVTA.355,356,361 Compared with EVLA, patients treated with
UGFS have somewhat less post-operative pain, but no dif-
ference could be found compared with RFA.328
The results (occlusion rates and side effects) of EVTA in the
treatment of saphenous vein reﬂux also depend on a good
technique (e.g. detailed pre-operative ultrasound, correct
positioning of the catheter or the ﬁbre tip, targeting injection
of tumescent ﬂuid, regular pull back speed). The vein to be
treated should be emptied of blood far as possible.4.7.1.2. Small saphenous vein. Scientiﬁc evidence. EVTA of
the SSV has excellent early and mid-term results.386,388,389
Access at the lateral malleolus results in a higher pares-
thesia rate compared with mid-calf access, because of the
proximity of the sural nerve to the SSV in the distal part of the
calf.386 EVLA of the SSV is associated with a signiﬁcantly
higher incidence of sensory disturbance compared with EVLA
of the GSV.387 SPJ ligation and stripping of the SSV often fails
because of the complex anatomy.360
Compared with surgery, EVTA seems to be more efﬁcient
and results in fewer post-operative side effects (less pares-
thesia, pain, and a faster return to normal activities).388
UGFS for the treatment of SSV incompetence can be an
alternative to EVTA and surgery. Two articles on UGFS
showed success rates varying from 82% to 100% (follow up
1.5e60 months). Thrombophlebitis (5%) and hyperpig-
mentation (24%) were common complications.326,360,417
There are no RCTs comparing foam sclerotherapy with
surgery or EVTA in treatment of SSV incompetence.4.7.2. Mechanochemical endovenous ablation
Introduction. Recently, a new hybrid (dual injury) technique
has been developed (ClariVein Vascular Insights, Quincy, MA,
USA). Endomechanical abrasion is produced by the tip of thecatheter’s rotating wire (mechanical component) and endo-
venous chemical ablation via the simultaneous injection of
sclerosant over the rotating wire (chemical component). This
technique is under development as the optimal dosage of
sclerosans still needs to be determined.
Scientiﬁc evidence. To date, there have been only two
cohort studies including a small number of patients treated
with MOCA.351,418 The occlusion rate at 6 months is 96.7%
and side effects seem to be minimal.4.8. Surgery of the superﬁcial veins
Introduction. For many years the gold standard for treat-
ment for CVD patients with superﬁcial venous incompe-
tence was surgery.4.8.1. High ligation with/without stripping
Scientiﬁc evidence. It has been reported that surgical
treatment of varicose veins is superior to conservative
management. In the REACTIV trial,419 the results of sur-
gery were compared with results of compression alone in
246 patients with uncomplicated varicose veins, the
surgical treatment comprising high ligation/stripping (HL/
S) of the GSV and multiple phlebectomies.420 At 2-year
follow up the results showed more symptomatic relief,
better cosmetic results, and much improved QoL for
surgery compared with conservative management by
compression.
In a prospective cohort study, 203 consecutive patients
who underwent varicose vein surgery were monitored, and
reported an improvement in QoL 2 years after surgery, with
a signiﬁcant improvement in the health related AVVQ score
and the SF-36 score.421 In addition, improvement in QoL
from varicose vein surgery has been shown to be statisti-
cally signiﬁcant and clinically relevant.422Comparative studies relating to traditional surgical
treatment compare isolated HL and HL/S.423e426 In a ran-
domized trial in 100 patients and 133 legs, HL was
compared with HL/S.424 The need for reoperation was 6% in
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who underwent HL alone (p < .02). In another study it was
shown that the HL group and the sclerotherapy group with
intention to close the GSV, had signiﬁcantly higher recur-
rence rates than HL/S at 4 years.425 Cosmetic results, both
judged by the patient and the surgeon, were signiﬁcantly
better (p < .05) in the stripped limbs than in the limbs with
HL and sclerotherapy.426 They also found that CW Doppler
evidence of reﬂux of the saphenous vein was less frequent
(p < 0.001) after the stripping operation. Better results
after aggressive and extensive surgical treatment of the
reﬂuxing veins and the sources of the reﬂux were reported.
A randomized trial showed a signiﬁcant reduction of risk of
re-operation in a HL/S group compared with a HL alone
group at 11 years of follow up, even if there was no dif-
ference for the rate of visible recurrent veins.423
In a RCT it was shown that patients in whom the stump of
the GSV had been invaginated with a non-absorbable suture,
had less neovascularization in comparison with those who
had the endothelium of the stump exposed.427 According to
a single centre prospective cohort study, interposition of an
anatomical barrier, by closing the cribriform fascia after SFJ
ligation, also reduced ultrasound detected neovascularization
at the SFJ after 1 year.428 In a RCT of 389 limbs by van Rij,
polytetraﬂuoroethylene (PTFE) patch coverage of the SFJ
created a signiﬁcant reduction of recurrence at 3 year follow
up by reducing neovascularization at the groin.120 The po-
tential beneﬁt of inserting a PTFE patch in recurrent varicose
vein operations could not be proven in another small RCT.429
Traditional HL/S has evolved towards a less invasive
technique by invagination under tumescent local anaes-
thesia, giving post-operative results as good as endovenous
ablation techniques or foam sclerotherapy in terms ofhaematoma, pain, and QoL as shown by Rasmussen in a
randomized control study.328 A non-comparative prospective
study showed that the use of isotonic sodium bicarbonate as
excipient for tumescent anaesthesia reduced intra-
operativepain and improved cost-effectiveness of surgery.430
As endovenous procedures have shown good results
without HL, stripping of the saphenous vein has also been
described without HL. A retrospective study showed that
stripping of the GSVwithout HL led to low neovascularization
and SFJ reﬂux rates at 3 year follow up (0.9% and 1.8%,
respectively).431 In a RCT at 8 year follow up, a group treated
by stripping without HL had signiﬁcantly less recurrence than
a group treated by HL/S (9.8% vs. 29%, p ¼ .014).432
Several RCTs have been performed comparing HL/s with
endovenous techniques (EVLA, RFA, foam sclerotherapy).
Among them, Rasmussen published a four arm RCT
comparing HL/S under tumescent local anaesthesia by
invagination stripping with EVLA, RFA, and foam sclero-
therapy. The results showed that the post-operative average
pain scores at 10 days were signiﬁcantly lower in the groups
treated with RFA and foam sclerotherapy compared with
HL/S and EVLA, with a shorter time to resumption of normal
activities and work. But the VCSS, the AVVQ scores, and the
clinical recurrence were not different between HL/S and the
other treatments at 3 years. The conclusion was that
beyond a higher pain score in the post-operative period and
a higher total cost for HL/S and EVLA, the efﬁciency of the
four modalities was not signiﬁcantly different.433
There is no evidence in the literature for continuing in-
dications for HL/S, unless there is lack of availability of the
endovenous techniques for ﬁnancial or other reasons. On
the other hand, HL/S is not inferior compared with the new
modalities of treatment in the mid term.
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Scientiﬁc evidence. The technique of ambulatory phlebec-
tomy (AP; stab or hook or mini-phlebectomy) was described
by Muller in 1966 with removal or avulsion of varicose veins
through small incisions performed with hooks and for-
ceps.15 Numerous authors have reported that ambulatory
phlebectomy is a safe and immediately effective procedure
for the treatment of varicose veins,315,434e438 which can be
done under local anaesthesia in an ofﬁce based setting.
Phlebectomy can be considered as an adjunctive treat-
ment in association with stripping or endovenous ablation of
the main reﬂuxing truncal vein,439e442 or as the exclusive
procedure for the treatment of varicose veins.15,315,435,443,444
A randomized study showed that ambulatory phlebec-
tomy compared with liquid sclerotherapy plus compression
for accessory vein incompetence caused signiﬁcantly fewer
recurrences at 1 and 2 years of follow up (respectively, 1/48
vs. 12/48 and 1/48 vs. 18/48 p < .001).315
Some publications advocate limiting the treatment to
thermal ablation of the SV without treating the tributary
varicose veins.445,446 According to these papers, secondary
treatment (foam sclerotherapy, phlebectomy, stripping) for
residual varicose veins was only necessary in 17e62.5%
after a short follow up period (3e9 months). On the con-
trary, another prospective study in 67 patients showed that
the performance of concomitantly performed phlebectomy
with an EVLA of the saphenous vein obviates the need for
subsequent procedures.447 The authors found that an
additional treatment by sclerotherapy or by phlebectomy
was performed in only 4% and 1% at 1 and 12 weeks. In a
randomized study of 50 patients between EVLA alone and
EVLA with concomitant ambulatory phlebectomy (EVLA/
AP), it was shown that at 3 months in the EVLA/AP group
the requirement for a secondary procedure was less com-
mon (1/25 vs. 16/24, p < .001), the VCSS was lower
(0(0 þ 1) vs. 2 (0e2), p < .001), and the AVVQ score was
better (7.9 vs. 13.5 p < .001).4484.8.3. Ambulatory Selective Varices Ablation under Local
anaesthesia
Introduction. The Ambulatory Selective Varices Ablation
under Local anaesthesia (ASVAL) method, consisting of single
phlebectomies with preservation of the saphenous trunk, is
based on the concept of ascending or multifocal evolution of
varicose veins. According to this pathophysiological concept,
progression of the disease could begin in subcuticular veins,
outside the saphenous compartment, creating a dilated and
reﬂuxing venous network. When this reﬂuxing network be-
comes large enough, it could create a “ﬁlling” effect in theintrafascial saphenous vein, leading to decompensation of
the saphenous vein wall, moving on to eventually reach the
saphenofemoral or saphenopopliteal junction.
Scientiﬁc evidence. The theory for the development of
varicose veins is historically based on the descending theory.
Anatomical, DUS examination, and morphological informa-
tion conﬁrmed the theory that the reﬂux begins at the
saphenous junctions and progresses downwards through the
saphenous axis leading to venous hypertension, wall dilata-
tion, and dilatation of tributaries which become varicose
veins. Cotton reported in an anatomical study that normal
veins have a signiﬁcantly higher number of valves than vari-
cose veins.90 Cooper assessed in a retrospective analysis of
venous DUS examinations that the incompetence of the SFJ
has a major inﬂuence on the extension of the reﬂux and that
the venous incompetence was most commonly proximal in
presence of varicose veins.449 Takase described numerous
alterations in structure of valves induced by venous hyper-
tension in association with varicose veins.450
However, numerous publications challenge the theory of
descending disease progression, citing the possibility of local
or multifocal early distal evolution, sometimes ascending or
anterograde, based on precise and detailed DUS in-
vestigations.49,431,451e456 The fact that the terminal valve at
the SFJ is frequently competent (in >50% of cases) in the
presence of truncal reﬂux has been clearly proven.449,457e459
The disappearance of reﬂux in the GSV following phle-
bectomy460e463 or after thermal ablation of an incompetent
tributary464 has been reported in the literature. Quill and
Fegan also found such reversibility of the saphenous reﬂux
following sclerotherapy.465 The diameter of the GSV was
observed to be reduced after ablating a reﬂuxing
tributary.466
In addition, the evolution of CVD, whether ascending
or descending, remains largely unknown, as prospective
longitudinal studies with a lengthy period of observation
and a large sample size, are missing and RCTs are needed.A retrospective cohort of 303 limbs treated by ASVAL re-
ported complete abolition of the saphenous reﬂux after 1, 2,
3, and 4 years in 69.2%, 68.7%, 68.0%, and 66.3% of cases,
respectively, and reduction in SFJ vein diameter, marked
symptom relief, and low recurrence rates.431 In this study, the
cohort of patients operated onwith ASVALwas younger,more
frequently asymptomatic, with a less extensive reﬂux, and
lower average diameter of the SFJ comparedwith the patients
who underwent stripping during the same period of time.
In a prospective study including 94 patients with large
varicose tributaries and GSV reﬂux assessed by DUS
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GSV reﬂux in 50% of the cases, with a signiﬁcant reduction
of the GSV diameter and a signiﬁcant improvement of the
AVVQ score.4674.8.4. Cure conservatrice et Hémodynamique de l’Insuf-
ﬁsance Veineuse en Ambulatoire (CHIVA)
Introduction. CHIVA was described by Franceschi in 1988. It
aims to improve the haemodynamics of the superﬁcial
venous network by splitting the column of hydrostatic
pressure and disconnecting venovenous shunts by inter-
rupting the incompetent trunks at strategic levels (SFJ,
perforating veins) depending on a precise pre-operative
DUS examination, to obtain a well-drained superﬁcial
venous system with low pressure and high ﬂow.
Scientiﬁc evidence. One RCT, concerned with treatment of
venous ulcers, showed that the group treated by CHIVA had
a similar healing rate (100% vs. 96%) and a lower recurrence
rate (9% vs. 38%) at 3 years follow up than the group
treated by compression.468
The clinical and DUS recurrence of varicose veins was
studied in two RCTs: the results were in favour of CHIVA
versus HL/S in both studies, 8% vs. 35% (p < .004) at 10
year follow up in one study469 and 31.1% vs. 52.7%
(p < .001) at 5 year follow up in the other.470
Some observations must be noted: in the paper by
Carandina, there is an important bias concerning the
randomization and follow up.469 In another study all
stripping procedures were done under general or
epidural anaesthesia whereas the CHIVA treatments were
performed under local anaesthesia, which acted as a
confounder for the evaluation of the post-operative side
effects.470 The most serious limiting concerns in both
studies were how “failure” by recurrence was deﬁned: it
is unclear if the presence of visible recurrent varicose
veins or the presence of reﬂuxing veins during the DUS
evaluation or both were considered to deﬁne the failure
of the treatment.4.8.5. Powered phlebectomy
Introduction. Transilluminated powered phlebectomy (TIPP)
consists of removal of large varicose vein clusters, with a
decrease in the number of incisions needed and a fasterperformance of the procedure, often combined with
saphenous vein ablation procedures or HL/S.
Scientiﬁc evidence. A published series of 114 patients, in a
prospective, non-comparative, multicentre, pilot study re-
ported the safety and efﬁcacy of TIPP.471 The patients, an
independent nurse, and the surgeon subjectively scored the
evaluation of outcomes in this study.
Other authors have stated in observational studies that a
learning curve exists to minimize bruising and that other
local complications may vary.472e474 Complications
observed include haematoma (4.9e95%), paresthesias and
nerve injury (9.5e39%), skin perforation (1.2e5%), super-
ﬁcial phlebitis (2.4e13%), swelling (5e17.5%), and hyper-
pigmentation (1.2e3.3%).475,476
More recently, a new system with important technical
modiﬁcations (lower oscillation frequency, larger volume of
tumescence, dermal drainage, ﬂushing of hematoma, and
residual tissue fragments), has improved the results of TIPP
with a lower rate of complications.477
A limited number of studies with many limitations (pilot
study, non-randomized, observational) have been published
and clearly lack data to show a signiﬁcant advantage of TIPP
over phlebectomy. It seems that the newer generation
system and modiﬁed technique enable TIPP to be less
invasive. Further studies are required to conﬁrm the po-
tential beneﬁts of TIPP.4.9. Treatment of deep vein pathology
Introduction. Annually one to two adults per 1,000 in the
Western population develop a DVT of the lower extremity.
Treatments using low molecular weight heparin (LMWH) or
unfractionated heparin and vitamin K antagonists in the
acute phase will not be discussed here. Despite adequate
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sions occur in a substantial number of these patients (20e
50%). The incidence of residual lesions is greater after a
recurrent DVT in the ipsilateral leg aggravating venous hy-
pertension because of deep venous obstruction and
valvular incompetence. The effect of this is the develop-
ment of oedema and dysfunction of the (micro)circulation,
which can lead to the clinical characteristics of post-
thrombotic syndrome (PTS). Also in well or partially
recanalized veins, residual venous obstruction may be
important, because the scarred venous outﬂow causes
increased outﬂow resistance, especially during and after
activity. As a result of chronic venous obstruction, collat-
erals develop, which partly take over the outﬂow capacity
of the thrombosed venous segments. However, these col-
laterals often feature a relatively low outﬂow capacity, and
are mainly used when venous pressure rises signiﬁcantly.
These collaterals are clinically visible at the level of the
thigh, lower abdomen, and pubis. Less commonly, the
cause of obstruction is extrinsic compression on the vein,
for example by a malignant tumour. There are also speciﬁc
iliac vein compression syndromes caused by non-
thrombotic iliac vein lesions (NIVL) such as May-Thurner
syndrome, in which the left common iliac vein is com-
pressed between the right iliac artery and the spine. There
are several forms of congenital deep venous anomalies
causing obstruction of the outﬂow tract. One severe
anomaly is atresia (congenital absence) of the IVC in which
the sub-hepatic segment of the IVC has not developed. This
may cause CVD because of outﬂow obstruction, often
complicated by recurrent ilio-femoral DVT and subsequent
post-thrombotic problems.478
In patients who have suffered from extensive DVT, apart
from residual venous obstruction, deep venous reﬂux may
occur, secondary to valvular damage. However, deep venous
reﬂux can also be induced by a very important proximal
outﬂow obstruction, causing dilatation of the deep veins in
the leg, and eventually failure of the valves to close
completely. The increased hydrostatic pressure leads to
venous hypertension, damage of the microcirculation, and
symptoms and signs of CVD. In some patients there may be
a congenital hypo- or aplasia of valves in the deep venous
system. This form of deep venous reﬂux is very rare.
The current standard treatment for symptoms and signs
of chronic venous obstruction or deep venous reﬂux is
compression therapy. However, its effectiveness may be
suboptimal in selected cases, especially when compression
therapy has limited effect on venous symptoms or the
compliance is poor.
4.9.1. Treatment of chronic deep venous obstruction
This can be performed either by percutaneous transluminal
angioplasty (PTA) and stenting, or by surgical correction,
usually bypass.
4.9.1.1. Percutaneous transluminal angioplasty and stent-
ing. Introduction. The endovenous treatment of iliocaval
obstruction includes traversing the obstruction with a guide
wire (occlusions need to be recanalized, i.e., a new lumencreated), followed by placement of a stent to cover the
obstructed vein segment. Self-expandable stents should be
used in the veins, ideally with a high radial force and suf-
ﬁcient ﬂexibility. The aim is for the stent to support the vein
wall and prevent recoil/collapse, and thereby to maintain
patency in the long-term. The largest longer term experi-
ence reported from multiple centres utilizes a braided stent
made of elgiloy (main content cobalt, chromium and
nickel). Although clinical results are favourable, these stents
have potential design inherited disadvantages, mainly
foreshortening and rigidity, and could possibly be
improved. Recently, dedicated venous stents of nitinol
(nickel and titanium) have therefore been designed to
speciﬁcally treat venous obstructions with these disadvan-
tages in mind. Nitinol is commonly used in the arterial
system and is known for its superelasticity and shape
memory (recovers its designed form at body temperature).
Clinical results using dedicated venous stents and com-
parison between different types of stent are lacking. The
optimal design and material of a venous stent is presently
not known.
In the arterial system, in most cases it is sufﬁcient to use
PTA alone. In the venous system, PTA must always be
complemented by a stent placement to avoid collapse of
the vein.26,479,480
Scientiﬁc evidence. Sixteen articles have been identiﬁed
related to PTA and stenting.479e494 Fifteen articles are non-
comparative in nature, with only four studies having a
prospective design. The methodology is generally moder-
ately clearly described and follow up varies from 2 to 144
months. Often there is no Kaplan-Meier survival analysis
performed to assess patency rates; however, some studies
with longer follow up report Kaplan-Meier data. Potential
confounding factors related to clinical outcome are often
not described, frequently additional treatment of the su-
perﬁcial system is performed during follow up. One study is
a retrospective, comparative study.482 This study has a large
proportion of C6 patients, particularly in the intervention
group, with a short follow up. There is a possible selection
bias, as the inclusion and exclusion criteria are poorly
described and it is not clear why patients are included in
either the intervention or control groups.
In seven studies with a total of 426 legs there was NIVL,
often May-Thurner syndrome, and post-thrombotic pathol-
ogy present.479,480,482,483,489,492 Technical success was ach-
ieved in 87e100% of cases, with an average follow up of 45
months (range 4e120 months). Primary* patency was 78%
(59e94%), assisted primary patency** 83% (63e90%), and
secondary patency*** 93% (72e100%). Ulcer healing rates
ranged from 47% to 100%,479,482,483,487,492 with 8% to 17%
ulcer recurrence rates; patients with patent reconstruction
performed generally better.479,487 Reduction of pain was
observed in 48% of the patients and 61% showed reduction
of oedema.490 In four studies, with a total of 1,000 lower
extremities, NIVL was speciﬁcally assessed.484,485,487,493
Technical success was achieved in 96e100% of cases, with
a follow up of 59 months (6e72 months). Primary* patency
was 85% (79e99%), and assisted primary** and secondary
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82% to 85%,485,493 with 5% to 8% recurrence.485,487 There
was statistically signiﬁcant improvement at all points of the
CIVIQ,487 and in the VAS and QoL scores.487,493 Oedema
decreased in 32% to 89% of cases,485,487,493 and hyperpig-
mentation improved in 87%.485
In six studies with a total of 921 legs, secondary (post-
thrombotic) obstruction was speciﬁcally examined.481,486e
488,490,491 Technical success was achieved in 93e100% of
cases, with a mean follow up of 46 months (2e72 months).
Primary patency* was 57% (50e80%), assisted primary
patency** 80% (76e82%), and secondary patency*** 86%
(82e90%). Ulcer healing ranged from 63% to 67%,486,490 with
0 to 8% recurrence.487,490 There was statistically signiﬁcant
improvement at all points of the CIVIQ487 and VCSS491 scores.
Oedema decreased in 32e51% of cases.486,487,490* Primary patency: the vein is open without any
additional intervention.
** Assisted primary patency: the vein is patent, but an
additional intervention was needed to keep the vein
patent.
*** Secondary patency: the vein is patent after one or
more additional interventions were required to treat
an occlusion of the vein.Stent placement is safe with low mortality and morbidity.
Stents in the external iliac vein may cross the inguinal lig-
ament to “land” in the common femoral vein. It has been
shown that in two thirds of patients with post-thrombotic
disease it is necessary to implant stents down to the
groin below the inguinal ligament to improve inﬂow into
the reconstructed iliac veins.487,491 Interventions distal to
the groin, including endophlebectomy or stenting further
down into the femoral vein or profunda femoral vein are
not yet validated.
4.9.1.2. Open bypass procedures. Scientiﬁc evidence. Two
studies from the same institution were identiﬁed, withdifferent types of surgical bypasses, that is femoro-femoral
bypass (Palma procedure, using GSV or polytetraﬂuoro-
ethylene bypass), femoro-iliac-inferior vena cava bypass, spiral
vein grafts, and femoral vein patch angioplasty.495,496 The
most recent report also includes the data of the ﬁrst publi-
cation and data about hybrid reconstructions (endo-
phlebectomy, patch angioplasty, stenting).495 Both studies are
retrospective in nature and often include patients who have
already had previous venous interventions, which are not
clearly described. A second problem with these studies is that
different procedures were performed. Results are not always
entirely clear, although Kaplan-Meier analyses were calcu-
lated. In these studies with a total of 110 legs and a follow up
of 31 to 41 months, there was 89% technical success.495 Pri-
mary patency of 42% and secondary patency of 56% were
achieved at 60 months. Ulcer healing was not registered.
AbuRahma reported a low clinical success and primary
patency rate for saphenopopliteal venovenous bypasses
(May-Husni procedures) of 56% after 66 months.497
New externally reinforced, ringed, grafts with large di-
ameters and coating may affect future results in a positive
fashion. Selectively constructing an AV-ﬁstula may also in-
ﬂuence patency positively.
4.9.2. Treatment of deep venous incompetence
Introduction. Deep venous incompetence can be divided into
primary and secondary forms. In primary incompetence, the
structure of the valve sometimes remains intact and is
therefore suitable for external or internal repair (valvulo-
plasty). More commonly there is valvular incompetence
caused by DVT. This secondary, post-thrombotic incompe-
tence is caused by a destruction of the valve as a result of the
inﬂammatory response in the thrombus, vein wall, and valve.
There are twooptions for reconstruction.One is to replace the
affected valve by transposition or transplantation of a vein
segment containing a valve; the second is to create a neovalve
from the thickened vein wall.
712 C. Wittens et al.Scientiﬁc evidence. A total of 24 articles were identiﬁed
that describe the non-conservative treatment of deep
venous reﬂux.498e520 There were 19 retrospective, one
prospective case series, and four prospective cohort
studies. In addition, one meta-analysis520 was performed. A
wide variety of surgical techniques were described,
including: internal valvuloplasty, external valvuloplasty,
valvuloplasty through external “banding”, creation of a new
valve from the local vessel wall (“neovalve”), transposition
of the incompetent vein on to a competent vein, trans-plantation of an autologous valve bearing vein segment to
an incompetent vein in the leg, and other less common
techniques of valve repair. Often, these operations were
combined with surgical treatment of incompetent superﬁ-
cial or perforating veins during or just before or after deep
venous surgery, which makes the interpretation of the re-
sults rather difﬁcult. In general, very heterogeneous pop-
ulations, often with only small patient numbers (between
20 and 50), were described or patient history and de-
mographics were simply not mentioned. Outcome mea-
sures used were heterogenous. In conclusion, it can be
stated that the durability of all of these techniques cannot
be derived from the available literature.
Summary. In general, good short-term results are
described in all the above mentioned studies for all
techniques. Technical success of the operation is close to
100%, when it is described. Competence of the replaced
or repaired valve during follow up is variable between
35% and 100% at a follow up of up to 144 months.498e520
There seems to be a trend in the literature, that valvulo-
plasty and creating a neovalve leads to better results than
transposition or valve transplantation. Success rates of
70% are reported after valvuloplasty in primary incom-
petence versus 50% after transposition or transplantation
in post-thrombotic patients at 60 months.521 Overall, ulcer
healing varies between 54% and 100% up to 5 years.
As no comparative studies have been performed, it is
not possible to indicate which valve (re)construction
techniques or other invasive treatments should be per-
formed and at what timing, in patients with deep venous
incompetence.Most patients with deep venous incompetence can be
treated with conservative measures alone. A surgical
correction is indicated only when, despite the use of
adequate compression therapy and a strict adherence to
lifestyle advice, severe symptoms persist, such as leg ulcers.
Surgical repair of deep venous incompetence cannot be
considered as a replacement therapy, but it is performed in
addition to conservative measures and surgical treatment of
superﬁcial venous incompetence, and, if necessary, perfo-
rating vein incompetence.In addition to all invasive treatment options, compression
therapy is mandatory, presumably lifelong. Patients with
post-thrombotic changes may continue to suffer from
venous reﬂux (e.g. calf veins) and/or obstruction.
Compression therapy improves venous outﬂow and may
enhance the patency of the reconstruction.
Therapeutic anticoagulation (AC) with coumadins or
LMWH is necessary after PTA and stenting, at least for
patients with chronic obstruction after DVT. The duration of
AC is unclear and should last at least 3 months. Some au-
thors recommend lifelong AC. LMWH and antiplatelet drugs
are recommended by some authors for treatment after PTA
and stenting of the deep venous system in NIVL patients.CHAPTER 5: RECURRENT VARICOSE VEINS
Introduction
Varicose vein recurrence following surgical intervention is a
common problem for both patients and clinicians. Whether
after open surgery or endovenous intervention, mid-term
recurrence rates remain in the region of up to 35% at 2
year follow up, and 65% at 11 year follow up.423,522e524
According to an international consensus meeting held on
recurrent varices after surgery (REVAS), the deﬁnition of
recurrent varicose veins is as follows: “the existence of
varicose veins in a lower limb previously operated on for
varicosities, with or without adjuvant therapies, which in-
cludes true recurrences, residual veins and new varices, as a
result of disease progression.”107,525,526
In the more recently published “Vein Term Update,” a
new acronym has been introduced to describe both
Table 13. Causes of recurrent varicose veins (least to most
common).
Tactical error e 4% Persistent venous reﬂux in




Technical error e 5.3% Persistent venous reﬂux due
to inadequate or incomplete
surgical technique
Neovascularisation e 13% Presence of reﬂux in a
previously ligated SFJ or SPJ
caused by development of
incompetent tortuous veins
linked to thigh (or calf)
varicosities
Disease progression e 15% Development of venous reﬂux
secondary to the natural
evolution of the disease
Management of Chronic Venous Disease 713recurrent varices (i.e. those presenting de novo in an area
previously treated successfully) and residual varices (i.e.
those remaining after treatment).1 PREVAIT stands for
PREsence of Varices (residual or recurrent) after InTerven-
tion and deﬁnes recurrent varicosities following both sur-
gery and endovenous intervention (thermal, ultrasound
guided foam sclerotherapy [UGFS]).
Recurrence can be classiﬁed according to clinical criteria
and duplex ultrasound (DUS) examination. Clinical recur-
rence has to be further deﬁned by DUS examination.
5.1. Etiology
The etiology of recurrent varicose veins is still poorly un-
derstood. It was originally thought that these were largely
tactical and technical errors resulting from poorly planned
or completed procedures.107,168 There is, however, evidence
suggesting that factors such as neovascularization may be
involved in recurrence.167,524,527
The sources of reﬂux feeding recurrent varicosities,
assessed by venous DUS, can be multiple, but have been
reported most commonly at the SFJ.107 A multicentre study
identiﬁed incompetence at the level of the junction in 47%
of their patients: 10% had no identiﬁable source of reﬂux;
75% of legs assessed had incompetent perforator veins,
whereas in 17% it was of pelvic or abdominal origin.
Pelvic vein reﬂux has been identiﬁed as an important
contributing factor to varicose vein recurrence.528 It is
particularly common in multiparous women, having been re-
ported in 44% of parous and 5% of nulliparous asymptomatic
women.529 Pregnancy increases blood volume and causes
compression of the pelvic veins secondary to the gravid
uterus, resulting in pelvic vein incompetence.530 In addition to
mechanical compression, hormonal effects may also be
implicated in the development of varicose veins in pregnancy,
with both oestrogen and progesterone receptors present in
normal and varicose vein walls.531e533 Venous obstruction,
secondary to DVT, or direct compression, secondary to pelvic
pathology, may also contribute to varicose vein recurrence.
A prospective study of 113 limbs identiﬁed four main
causes of recurrence (Table 13).166
Tactical error. Tactical error refers to errors in pre-operative
planning. This includes erroneous identiﬁcation of the reﬂux-
ing segment. With the advent of improved pre-operative im-
aging in the form of venous DUS examination and with
minimally invasive ultrasound guided techniques providing
targeted treatment, human error should play a lesser part in
the development of recurrence.534 Pre-operative DUS imaging
has been shown to improve the results of varicose vein sur-
gery, based on correct identiﬁcation of incompetence in the
GSV, AASV, and/or SSV system.534 Tactical errors also include
decisions regarding the surgical approach by the treating
physician that may result in recurrence.
There is evidence that stripping or ablating the GSV, as
opposed to performing high ligation only, results in reduced
recurrence rates. A randomized trial of SFJ ligation  GSV
stripping revealed recurrence rates at 2 years of 43% in the
ligation group and 25% in the ligation þ stripping group.522In endovenous intervention, the persistence of a below
knee reﬂuxing GSV segment (i.e. ablation of the above knee
segment only) was found to be associated with recurrence,
reﬂux, and the need for further intervention.535 However,
the increased risk of paraesthesiae and saphenous nerve
damage following treatment of the below knee GSV should
be taken into account.536
When planning intervention in CVD, it is of paramount
importance to carefully discuss the risks and beneﬁts of
each option with the patient.
Technical error. Technical error refers to inaccurate treat-
ment at the time of surgery or endovenous intervention.
This may be related to poor access, poor visualization of the
target vein segment and the SFJ or SPJ (in ultrasound
guided endovenous procedures), or inexperience.
Historically, a lack of experience by the operating surgeon
has been blamed for high recurrence rates. However, there is
evidence against this, suggesting that human, or technical
error, plays a lesser role in the development of recurrence
compared with neovascularization and disease
progression.166,537
Neovascularization. Neovascularization refers to the for-
mation of new veins, typically at the site of the previous
ligation of the GSV or SSV. This results in reconnection of the
deep vein with a residual main saphenous trunk (if not
stripped) or with superﬁcial tributaries, eventually resulting
in clinical recurrence.538 After GSV stripping, revasculariza-
tion of the saphenectomy track has been observed, seen as
multiple tortuous venous channels in the track of the pre-
viously stripped GSV.539
On DUS examination, neovascularization is visualized as a
network of complex, tortuous vessels, connecting the end,
or stump, of the GSV or SSV to a tributary in the thigh or
calf.148,164 It is important to note that different degrees of
DUS-detected neovascularization exist; neovascularization is
present in 25e94% of recurrent varicose veins.540,541
However, assessment of neovascularization on DUS exami-
nation can be challenging.
714 C. Wittens et al.The mechanism for the development of angiogenesis and
neovascularization is still unclear.524 Mediators such as
growth factors (e.g. vascular endothelial growth factor),
matrix metalloproteinases, and angiopoietin are
involved.164 A number of theories have been postulated to
explain why neovascularization develops post-operatively. It
may be part of the physiological healing process after
venous surgery. In the track where the original vein was
stripped, the post-operative haematoma may organize, with
development of capillaries, venules, and ﬁnally tortuous
recurrent veins. Altered venous haemodynamics may lead
to its development. Or ﬁnally, it may be a physiological
response to venous disconnection.
Either way, neovascularization has been found to account
for a considerable proportion of recurrences and there is
evidence suggesting it plays a greater role in open surgery
than in endovenous therapy.166 DUS examination detected
neovascularization in 18% of the surgery group and 1% of
the Endovenous Laser Ablation (EVLA) group, while clinical
recurrence rates were similar.167
However, the presence of DUS detected recurrence does
not necessarily mean a new intervention is needed. The rate
of re-operation following varicose vein surgery was shown
to vary according to the nature of the recurrence.534 DUS
detected neovascularization seldom required re-
intervention, whereas patients with recurrent or residual
varicose veins because of tactical or technical failure had
more re-operations during a follow up period of 7 years.
Disease progression. Disease progression accounts for a
large proportion of recurrences.166 The progression may be
multifocal, ascending, or descending. According to the
ascending pathophysiological principle, superﬁcial veins
may dilate and become varicose over time. According to the
descending principle, ongoing reﬂux at the SFJ or SPJ and/or
saphenous trunks may cause superﬁcial tributaries to dilate
and become varicose. As a result of disease progression,
incompetence can also develop in a previously untreated
saphenous trunk, for instance in the SSV, after previous
treatment of the GSV, or in perforating veins.
Recurrent varicose veins remain a poorly understood
entity with several proposed etiologic factors. Their inci-
dence and severity may be related to the original treatment
modality; however, disease progression may also play a
major role. Further studies are required to increaseunderstanding of their development at a molecular level to
enable the development of effective prevention and treat-
ment strategies for recurrent varicose veins.5.2. Risk factors
In addition to the aforementioned four factors, there is evi-
dence suggesting that the original intervention has an impact
on the likelihood of recurrence, although recurrence rates
are largely comparable among treatment modalities.166,5425.3. Diagnosis of recurrent varicose veins
DUS is the preferred diagnostic approach to investigate
recurrent varicose veins (see 3.2.3.3).5.4. Treatment of recurrent varicose veins
The management of recurrent varicose veins is a challenge
for the clinician. Repeated intervention is associated with
reduced patient satisfaction.166,543,544 Therefore, a less
invasive approach, consisting of multiple phlebectomies or
alternative techniques, has been advocated to replace
invasive redo surgery including re-exploration of the groin
or popliteal fossa.545,546 Extensive redo surgery should be
performed only in selected cases.
RFA and EVLA have been described as safe and effective
options for treatment of recurrent varicose veins.377,547,548
The pattern of reﬂux feeding the recurrence can be from
multiple origins, and the SFJ is often involved as a source.107
Recurrence may also be secondary to incompetent perfo-
rators or pelvic vein incompetence. If a truncal vein
segment is involved, this may be suitable for endovenous
ablation, which may re-establish competence in previously
incompetent perforating veins.547 Ablation of the reﬂuxing
axial segment has been reported to re-establish compe-
tence in previously incompetent perforator veins.547
When compared with conventional surgery in the treat-
ment of SSV recurrence, EVLA was found to have a higher
technical success rate and lower complication rate, particularly
with respect to sural nerve neuralgia (20% vs. 9%).549 RFA was
also found to be superior to redo groin surgery, with signiﬁ-
cantly lower pain scores, bruising, and procedure times.377
UGFS has also been used successfully in the treatment of
recurrence,323 although with lower success rates compared
with laser ablation.
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MALFORMATIONS
Introduction
CVD describes visual and functional abnormalities in the
peripheral venous system, affecting most commonly, but
not exclusively, the lower limbs. Classiﬁcation systems, such
as the CEAP classiﬁcation,109 have been employed to
differentiate between congenital, primary, secondary, and
unknown causes of CVD.
Congenital vascular malformations (CVMs) are present in a
very small proportion of patients. However, despite a limited
incidence, the magnitude and severity of their clinical mani-
festations can be striking. Congenital venous malformations
are disorders resulting from abnormalities in the development
of the venous system. Depending on the developmental ab-
erration, venous, arterial, and/or lymphatic channels may be
involved, resulting in heterogeneous clinical presentations.550
In this chapter, the classiﬁcationofCVMs is discussed, paying
particular attention to congenital venous malformations, as
well as syndromes affecting the venous system, suchas Klippel-
Trenaunay (KTS) and Parkes-Weber syndrome (PWS).
6.1. Pathophysiology
The pathophysiology of CVMs is unclear and may be sec-
ondary to sporadic mutations or a possible hereditary
component, although familial inheritance is rare. CVMs are
non-degenerative and non-inﬂammatory in origin and can
appear anywhere in the body.
Development of the circulatory and lymphatic systems
begins in the third gestational week, with the formation of
peripheral and central blood islands from mesoblastic cells.
In the ﬁrst developmental stage, proliferation and fusion of
these cells results in the creation of a primitive capillary
network. This is followed by retiform and plexiform stages as
the foetus develops. Ultimately, speciﬁc vessels enlarge to
contribute to the deﬁnitive circulatory system, while others
that are present only in the embryonic stages regress.550
Aberrant development at any of these stages can result in
CVMs. Importantly, if this occurs during the primitive capillary
stage, the abnormal embryonic vessels remain in the form of
clusters and do not differentiate into deﬁnitive vessels.
Furthermore, they are separate from themain venous trunk
and are therefore deﬁned as extratruncular.550 If the defect
occurs at a later stage, itmay lead to abnormalities in “named”
vessels, with resulting hypoplasia, aplasia, obstruction, or
dilatation. These are directly involved with the truncal venous
system, and are therefore classiﬁed as truncular. This distinc-
tion is important in the classiﬁcation of CVMs.
6.2. Classiﬁcation
Introduction. CVMs are challenging to understand and
deﬁne. A number of contributors have attempted to classify
these lesions, aiming to develop a universal system to
standardize their diagnosis and description, as well as to
improve communication among specialists reporting in the
literature. Different contributors have employed differingstandards for their classiﬁcations, including embryological,
anatomical, clinical, and haemodynamic criteria, resulting in
heterogenous classiﬁcation systems.550 The International
Society for the Study of Vascular Anomalies (ISSVA) aims to
further increase knowledge of the pathogenesis, diagnosis,
and treatment of patients with CVMs. Among its roles is
review of speciﬁc classiﬁcation systems.551
6.2.1. International Society for the Study of Vascular
Anomalies classiﬁcation
Mulliken and Glowacki ﬁrst introduced a biological classiﬁ-
cation based on pathological characteristics of the endo-
thelium and the natural course of the vascular lesion.552
This system made the distinction between vascular tu-
mours (of which haemangioma is the most common) and
vascular malformations (Table 14).
This classiﬁcation was redeﬁned553 and adopted by the
ISSVA. Again, the distinction was made between hae-
mangiomata and vascular malformations, which were sub-
divided into single system and combined lesions (e.g.
arterial and/or venous, and/or lymphatic; Table 15).
6.2.2. Hamburg classiﬁcation
The Hamburg classiﬁcation was developed in 1988554 and
approved by the ISSVA. This classiﬁcation system described
CVMs in terms of their anatomical and clinical characteris-
tics (i.e. arterial, venous, shunt, or combined) and the
embryological stage during which the malformation began
to develop (truncular or extratruncular).
This classiﬁcation system does not take into account
haemangiomata or lymphatic malformations, but adequately
describes lesions according to clinical and anatomical char-
acteristics and facilitates communication between different
specialties as a result of its descriptive nature (Table 16).
6.2.3. Puig classiﬁcation
A new classiﬁcation system was also developed by Puig,
describing the subgroup of venous malformations (VMs) in
terms of their anatomical characteristics and pattern of
venous drainage (Table 17).555 The authors used this clas-
siﬁcation system as a basis for interventional therapy,
particularly in assessing the suitability of paediatric patients
for sclerotherapy.6.3. Venous malformations
Venous malformations (VMs) are a subtype of CVMs. They
have an estimated incidence of 1e2/10,000 births, a
716 C. Wittens et al.prevalence of 1%, and are the most common type of
CVM.556
Etiology. The majority of isolated VM’s appear on a sporadic
basis with no hereditary component,557 although rare
autosomal dominant conditions such as familial cutaneo-
mucosal VM or glomuvenous malformation exist.556
Clinical characteristics. VMs may not be apparent from
birth, developing in later childhood or adulthood. Often
rapid growth occurs in puberty. The location of VMs is
relatively equally distributed: 40% occur in the head and
neck area, 40% in the extremities, and 20% in the trunk.558
VMs present as soft, compressible, blue-tinged masses
that, like veins, may change in size according to position or
expand with the Valsalva manoeuvre.558 Superﬁcial ecchy-
moses, teleangiectasiae or varicosities may be present. There
is no evidence of pulsatility, thrill, raised temperature, or
hyperaemia, differentiating them from arteriovenous mal-
formations (AVMs). VMs are most commonly found in the
skin and subcutaneous tissues; however, they can involve theTable 15. Tumours and Vascular Malformations.
Tumours












Single Capillary (C) (port wine stain, naevus
ﬂammeus)
Venous (V)
Lymphatic (L) (lymphangioma, cystic
hygroma)
Arterial (A)




with Klippel-Trenaunay Syndrome (KTS)]
- Capillary Venous Malformations
(CVM)




Capillary, lymphatico - arteriovenous
malformation (CLAVM)underlying muscle, bone, and viscera. If large in size, they
may cause pressure effects on surrounding structures and
planes, including bone, muscle, and subcutaneous tissue.
Importantly, VMs may be located intraorally and may
cause bleeding, speech impediments, and airway obstruc-
tion. VMs are also at risk of thrombosis and there is evi-
dence that the presence of VMs is associated with localized
intravascular coagulopathic features.559
Diagnosis. DUS examination is the preferred initial imaging
modality in the examination of VMs. It is safe, widely
available, rapid, non-invasive, and low cost. Patients with
VMs are young, so avoiding ionizing radiation is paramount.
DUS allows differentiation between high ﬂow (AVMs) and
low ﬂow (VMs, lymphatic malformations) CVMs. VMs are
usually compressible, heterogeneous masses, and appear as
hypoechoic, heterogenoeous lesions in the majority of cases
(82%). In a study of 51 soft tissue VMs, 16% had an iden-
tiﬁable pathognomic phlebolith on DUS.560
VMs may be difﬁcult to differentiate from adjacent fatty
structures. Fat suppression techniques, such as inversion
recovery sequences (Short Inversion Recovery, STIR), may
be helpful in characterizing lesions.
CT is of limited use because it requires ionizing radiation
and because of its poor lesion characterization, particularly
in cases where the VM is deep and adjacent to underlying
structures.556 In addition, the use of contrast CT may un-
derestimate the true lesion extent.558
MR imaging, with its superior soft tissue and lesion
characterization, is the preferred imaging modality to deﬁne
lesion extent and the relationship with adjacentTable 17. Puig Classiﬁcation.
Type I Isolated malformation without peripheral
drainage
Type II Malformation that drains into normal veins
Type III Malformation that drains into dilated veins/
venous ectasia
Type IV Malformation that represents dysplastic venous
ectasia
Table 16. Modiﬁed Hamburg Classiﬁcation.
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recovery sequences (Short inversion Time Inversion Recov-
ery, STIR), may be particularly helpful in characterizing le-
sions difﬁcult to differentiate from adjacent fatty
structures.561
Direct percutaneous phlebograpy entails ﬁne needle
puncturing of the VM and contrast injection under ﬂuo-
roscopy. It is the imaging modality of choice to diagnose
VMs in situations where previous imaging has been equiv-
ocal556 and is used during sclerotherapy procedures as an
initial diagnostic evaluation.
Management
The management of VMs involves a number of disciplines,
including surgery, dermatology, medicine or paediatrics, and
radiology. Clear communication between members of these
disciplines and a true multidisciplinary approach are
extremely important in the assessment and management of
patients with VMs.
Conservative. VMs can be a chronic, non-life threatening
condition with a potentially variable clinical picture. Mild
symptoms are successfully managed with conservative
measures, including limb elevation during sleep and
avoidance of activities that may exacerbate symptoms. Pa-
tients can have localized intravascular coagulopathy, which
may lead to thrombosis and paroxysmal pain.559 Aspirin and
prophylactic treatment with LMWH have been used in
selected cases as an adjunct to conservative treatment,556
while elastic compression garments have been employed
to provide symptomatic relief.562
Sclerotherapy. The rationale for using sclerotherapy to treat
VMs is the same as for treating varicose veins: to cause
damage to the venous endothelium. A sclerosing agent (e.g.
ethanol, sodium tetradecyl sulphate [STS] or polidocanol), in
liquid form or aerated to produce foam, is directly delivered
into the venous lumen via ﬁne needle injection under image
guidance (e.g. ultrasound, phlebography), allowing the agent
to directly interact with the endothelium.556
QoL measures following sclerotherapy to VMs have
revealed improved symptoms following therapy.563 Patients
with localized VMs did better than those with diffuse mal-
formations affecting whole muscles or compartments.
The choice of sclerosant agent is an important variable in
both the efﬁcacy and complication rate proﬁle of the
different agents. A large series reporting the use of ethanol
in 87 patients over 399 sessions has revealed initial success
rates of 95%, with no recurrence at follow up (average 18.2
months).564
Minor and major complication rates were 12.4%: ery-
thema, blistering, and localized skin ulceration or necrosis,
as well as DVT and pulmonary embolism (reported in 1.25%
and 0.25% of sessions, respectively) have all been reported.
Sodium tetradecyl sulphate (STS) has a more favourable
side effect proﬁle. A large series of 72 patients over 226
sessions revealed no major complications. Minor compli-
cations were present in approximately 3% of the sessions,
including ulceration, skin necrosis, and transient sensory
deﬁcits.565 According to this series, after treatment, 15% ofpatients became asymptomatic, 28% rated the therapy as
good, 24% were improved, 28% unchanged, and 5.6% felt
worse. Again, patients with inﬁltrative lesions reported
poorer outcomes than those with localized lesions.
Polidocanol has the lowest side effect proﬁle, with pain
and swelling being the most common complications.556 A
retrospective series of 19 patients with VMs found that,
after treatment, patients reported a decrease in pain and
signiﬁcant reduction in the size of the lesion.566
A prospective study compared use of UGFS with ultra-
sound guided liquid sclerotherapy in treatment of symp-
tomatic VMs. UGFS required a signiﬁcantly smaller volume
of sclerosant and had improved treatment outcomes
compared with liquid sclerotherapy.567
Surgical. The decision to treat VMs surgically should be
multidisciplinary. The main indications for treatment are
persistent pain, functional impairment, or cosmetic implica-
tions in head and neck lesions, as well as location posing a
realistic risk to the patient (e.g. lesions affecting the airway).558
Surgical resection is appropriate in patients with focal,
well-deﬁned VMs that are thrombosed and limited to a
speciﬁc area. However, many VMs are inﬁltrative and
involve more than one muscle group or fascial plane,
resulting in extensive debulking. In these cases, sclero-
therapy can be used as an adjunct.556 Truncular VMs with
deep venous abnormalities may require resection and deep
venous reconstruction. Extratruncular, diffuse VMs are best
treated with sclerotherapy.
Patients with VMs should be treated conservatively or
with sclerotherapy where possible.
6.4. Syndromes
Some forms of combined congenital vascular malformations
have been previously described as syndromes. The two
most important syndromes are KTS and PWS, and both will
be discussed in this chapter.
6.4.1. Klippel-Trenaunay syndrome
Maurice Klippel and Paul Trenaunay ﬁrst described this
condition in 1900, referring to it as “naevus vasculosus
osteohypertrophicus” after observing two patients with skin
lesions associated with asymmetric soft tissue and bone
hypertrophy.568
Vascular malformations can be single or combined
depending on the components of the circulatory system that
are involved in the lesion.553 KTS is a syndrome characterized
by capillary, venous, and lymphatic abnormalities, without
signiﬁcant arteriovenous shunting. It is a rare condition,
occurring in 1:20,000-1:40,000 live births with an unclear
cause.569 Patients with this condition are characterized by
the clinical triad of port wine stain, varicose veins, and soft
tissue and/or bone hypertrophy (occasionally hypotrophy).
6.4.1.1. Etiology. The genetic origin of KTS is still unclear.
The literature on the subject is heterogenous, varying from
sporadic cases568 to single gene defects.569
With regards to the development of clinical signs and
symptoms, several theories have been proposed. It is
thought that KTS presents as a consequence of a
718 C. Wittens et al.mesodermal abnormality during foetal development,
resulting in the maintenance of microscopic arteriovenous
communications in the limb bud, leading to the develop-
ment of naevi, hypertrophy, and superﬁcial varices.570
Other developmental theories include primary obstruc-
tion or atresia of the venous system (leading to increased
venous pressure, chronic venous hypertension, limb hy-
pertrophy, and varicose veins)571 and increased angiogen-
esis during development.572
6.4.1.2. Clinical characteristics. Clinical ﬁndings are usually
present at birth, but in some cases they may not be fully
apparent.573 Clinical features are variable, ranging from mini-
mal disease to disﬁgurement with a signiﬁcant cosmetic
impact.
Clinical signs: capillary malformation (naevus ﬂammeus).
In KTS patients typical capillary malformations are seen,
often described as “naevus ﬂammeus.” There are charac-
terized by reddish pink macules that are present from birth
but may not be visible until a few days after delivery.
Capillary malformations are present in KTS in up to 98% of
patients, making them the most common associated clinical
abnormality.574 They are usually multiple, affecting the lower
limb in 95% of cases, and can spread to the buttock or chest.
Rarely, the entire side of the body may be affected.
Clinical signs: varicose veins. Varicose veins are another
clinical feature associated with KTS. Abnormal veins can
manifest as anomalous lateral veins or persistent embryonic
veins. These are dilated and tortuous secondary to valvular
incompetence or deep venous abnormalities. In the Mayo
Clinic series, 72% of patients had atypical veins, the most
common abnormality being the persistence of a lateral em-
bryonic vein.575 The authors advised that the presence of a
large, persistent, superﬁcial vein in the lateral thigh that does
not join the deep system should alert the clinician to the
possibility of KTS. A smaller proportion of patients had an
anomalous medial vein or, more rarely, a suprapubic vein.
In addition to superﬁcial venous abnormalities, the deep
venous system also may be anomalous. Venous ectasia,
hypoplasia, aplasia, or the persistence of an embryological
sciatic vein are all manifestations of deep venous abnor-
malities in KTS.
Clinical signs: lymphatic hyperplasia. Lymphatic hyperplasia
is found in a large number of patients. This presents as
vesicles containing clear ﬂuid and may be associated with
marked lymphoedema, resulting in soft tissue hypertrophy
and leg length discrepancy. In a large series from the Mayo
Clinic, lymphatic hyperplasia was present in 67% of their
patients.575 Importantly, the presence of this triad was
variable. In 63% of patients, all three features were present,
while the remaining patients had two or fewer. Further-
more, most had lower limb malformations, mainly unilat-
eral. Only 30% suffered from upper limb malformations.
Patients with KTS are at increased risk of developing
supeﬁcial vein thrombosis, DVT and pulmonary embolism.569
Symptoms. The diagnosis of KTS is made according to the
presence of physical signs. However, patients may present
with symptoms, most commonly swelling, pain, bleeding from
superﬁcial varicosities, and superﬁcial thrombophlebitis.575Pain is a signiﬁcant complaint, with up to 88% of patients
experiencing varying degrees of discomfort.576 A number of
factors causing pain and discomfort in patients with KTS
have been identiﬁed, including varicose veins,CVI (C3eC6),
cellulitis, superﬁcial vein thrombosis, DVT, vascular malfor-
mations, arthritis, and neuropathic pain.569
6.4.1.3. Diagnosis. The diagnosis of KTS is largely clinical. As
for CVD, DUS examination is the gold standard to assess the
superﬁcial and deep venous systems in these patients. This
enables assessment of aberrant venous anatomy, as well as
conﬁrming the absence of any clinically signiﬁcant arterio-
venous shunting.
Plain radiographs are used to measure limb length in the
ﬁrst instance. Other helpful imaging modalities to assess for
venous abnormalities include MR imaging (useful to
differentiate between bone, fat, muscle hypertrophy, and
lymphoedema), MR angiography and/or venography, CT
imaging (helpful in assessing bony anatomy), and contrast
studies (arterial and venous), which allow delineation of the
deep venous system and collaterals, as well as revealing
localized vascular malformations.574
6.4.1.4. Management. KTS is a rare, complex disorder
requiring a multidisciplinary approach to its management.577
This involves a number of specialties, including paediatrics,
general medicine, orthopaedic, plastic and vascular surgery,
interventional radiology, cardiology, and physical therapy.578
The disorder is a mixed vascular malformation, with capil-
lary, venous, and lymphatic components. There is no cure for
the syndrome, and treatment is directed towards symptom-
atic management, secondary prevention of venous hyper-
tension, and preservation of functional integrity of the legs.579
Patients often do well without intervention; however,
absolute indications for treatment exist. These include
haemorrhage, infection, acute venous thromboembolism,
and refractory ulceration.578
Conservative treatment. The treatment of VMs is similar to
that of other forms of CVD. Limb elevation, compression
therapy (stockings or compression bandaging), and decon-
gestive physical therapy, in the form of massage, all can be
beneﬁcial in the management of the hypertrophied limb
affected by lymphoedema and CVI (C3eC6). Skin care is
paramount in patients at risk of developing cutaneous
manifestations of CVD, including ulceration.580
Because of the increased risk of venous thromboembo-
lism, AC may be considered in patients with recurrent epi-
sodes of superﬁcial or deep vein thrombosis.578
TCL therapy has been used in the treatment of naevus
ﬂammeus to lighten or, where possible, remove the cuta-
neous abnormality.
Surgical treatment. Surgical intervention is limited to those
patients who are not candidates for conservative treatment.
It is important to fully assess both the superﬁcial and deep
venous systems by DUS to evaluate the extent of VMs and
the patency of the deep venous system prior to performing
any surgical procedures.580
The Mayo Clinic has published the largest reported series
of patients with KTS.575 According to their experience, the
most common operations performed in these patients were
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plate, in a child to slow or halt the growth of a limb),
stripping of reﬂuxing truncal veins, debulking procedures,
and amputations. Nonetheless, they advised that patients
with KTS should be treated conservatively where possible.
Abnormal veins and obvious varicosities can be removed
where the deep venous system is competent and functional.
Otherwise, compression therapy has been used successfully
to reduce swelling and signs of venous disease.580
Incompetence of the main superﬁcial trunks in KTS patients
may not only be addressed by stripping, but also with more
modern technology in the form of endovenous thermal (laser
or radiofrequency) ablation or foam sclerotherapy.551,581
UGFS with STS and polidocanol has been used to treat
superﬁcial varicose tributaries with good cosmetic and
functional results, with a reduction in pain levels and in the
size of varicosities.566,579
Endovascular RFA has also been employed to treat
venous insufﬁciency in patients with this syndrome. Pa-
tients reported decreased leg pain, oedema, and varicose
vein prominence after intervention.551,582 In selected cases,
both treatment modalities can be used together for the
treatment of superﬁcial venous disease.581
Open surgery is not only limited to ligation and stripping, but
also includes deep venous reconstructions or entrapped
popliteal vein release in those cases where embryological ab-
normalities have left the patient with signiﬁcant deep venous
anomalies. Recurrence rates for treatment of VMs canbeup to
15%, but clinical improvement in patients is signiﬁcant and
further interventions may be performed if required.580
Limb hypertrophy, resulting in leg length discrepancy,
may be treated by epiphysiodesis in the growing child
where the difference is predicted to exceed 2 cm. Very
rarely, amputation is required where the size of the limb
affects the patient’s day to day functioning.583
6.4.2. Parkes-Weber syndrome
PWS presents similarly to KTS but has a distinct patho-
physiological mechanism. It was ﬁrst described in 1907 by
the physician Frederick Parkes Weber. The incidence is
sporadic, with no apparent racial or gender predilection.
6.4.2.1. Etiology. Unlike KTS, which is a low ﬂow malfor-
mation involving the capillary, venous, and lymphatic sys-
tems, PWS is characterized by fast ﬂow arteriovenous
abnormalities. It is present from birth and most commonly
affects the lower limbs. Persistent lateral thigh vein is un-
common, and lymphatic and soft tissue malformations donot usually occur.551 The presence of a fast ﬂow ﬁstula can
increase cardiac preload, leading to cardiac failure, and
even cutaneous ischaemia.
Originally thought tobea sporadic disease, there is evidence
that the RASA1 gene on chromosome 5 plays a signiﬁcant role
in the development of PWS. This gene mediates growth, dif-
ferentiation, and proliferation of several cell types, including
vascular endothelial cells.584,585 Mutations result in multifocal
capillary malformations with fast ﬂow vascular lesions.584
6.4.2.2. Clinical characteristics. PWS is characterized, like
KTS, by capillary cutaneous malformations and limb hyper-
trophy, in addition to AVMs. The connections between ar-
teries and veins are high ﬂow, and can result in skeletal or soft
tissue hypertrophy. Local effects of arteriovenous ﬁstulae are
prominence and dilatation of the superﬁcial veins secondary
to increased pressure. A bruit ormachinerymurmur is audible
and palpable throughout the cardiac cycle.
The presence of high ﬂow ﬁstulae prior to epiphyseal
union results in regional effects, including increase in bone
length, girth, and in the temperature of the affected limb.
Systemic effects are the result of the large ﬂow of blood
travelling from the arterial to the venous system. This can
result in a marked increase in cardiac preload, leading to
congestive cardiac failure.586
6.4.2.3. Diagnosis. Similar to KTS, DUS examination can be
very helpful in characterizing arterial and venous anatomy,
as well as in differentiating between high and low ﬂow
anomalies. Plain radiographs and MR imaging are helpful in
assessing the hypertrophied limb. MR studies also provide
assessment of lymphatic, venous, and soft tissue compo-
nents of the affected limbs.587 Arteriography and venog-
raphy can assess the circulatory anatomy and characterize
arteriovenous ﬁstulation.
6.4.2.4. Management. Conservative management, where
possible, is preferred. This includes prevention of trauma
and damage to the affected limb as healing may be
impaired and the patient is at an increased risk of bleeding
in the presence of AVMs. Lower limb swelling may be
managed with limb elevation and compression therapy.
Limb growth, similar to KTS, can be addressed with epi-
physiodesis where marked.
Fast ﬂow, signiﬁcant AVMs associated with clinical signs
(e.g. ulceration or congestive cardiac failure), are a potential
indication for intervention. This is in the form of arterial
embolization or surgical resection of the lesion.585,588 In
extreme cases, amputation may be required where the
affected limb is markedly impinging on a patient’s QoL.
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